ES2335636B1 - COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. - Google Patents
COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. Download PDFInfo
- Publication number
- ES2335636B1 ES2335636B1 ES200800596A ES200800596A ES2335636B1 ES 2335636 B1 ES2335636 B1 ES 2335636B1 ES 200800596 A ES200800596 A ES 200800596A ES 200800596 A ES200800596 A ES 200800596A ES 2335636 B1 ES2335636 B1 ES 2335636B1
- Authority
- ES
- Spain
- Prior art keywords
- agents
- cosmetic
- skin
- dermopharmaceutical
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 150
- 239000002537 cosmetic Substances 0.000 title claims abstract description 121
- 239000000693 micelle Substances 0.000 claims abstract description 86
- 210000003491 skin Anatomy 0.000 claims abstract description 62
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 48
- 239000004094 surface-active agent Substances 0.000 claims abstract description 48
- 210000004209 hair Anatomy 0.000 claims abstract description 25
- 210000000720 eyelash Anatomy 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 86
- 239000000284 extract Substances 0.000 claims description 84
- 239000003795 chemical substances by application Substances 0.000 claims description 71
- 239000002502 liposome Substances 0.000 claims description 49
- -1 alkyl glycosides Chemical class 0.000 claims description 46
- 230000015572 biosynthetic process Effects 0.000 claims description 41
- 239000002269 analeptic agent Substances 0.000 claims description 40
- 238000003786 synthesis reaction Methods 0.000 claims description 37
- 239000002671 adjuvant Substances 0.000 claims description 31
- 150000002632 lipids Chemical class 0.000 claims description 29
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 29
- 150000003904 phospholipids Chemical class 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 23
- 230000004888 barrier function Effects 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 208000035475 disorder Diseases 0.000 claims description 19
- 239000003921 oil Substances 0.000 claims description 19
- 230000007170 pathology Effects 0.000 claims description 19
- 235000019198 oils Nutrition 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 16
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 claims description 15
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 239000000787 lecithin Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 150000001412 amines Chemical class 0.000 claims description 12
- 229940067606 lecithin Drugs 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 11
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 239000006185 dispersion Substances 0.000 claims description 11
- 239000000194 fatty acid Substances 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 201000004384 Alopecia Diseases 0.000 claims description 10
- 201000004624 Dermatitis Diseases 0.000 claims description 10
- 239000006260 foam Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 235000010445 lecithin Nutrition 0.000 claims description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 9
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 9
- 229940073499 decyl glucoside Drugs 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- 230000035755 proliferation Effects 0.000 claims description 9
- 239000000243 solution Substances 0.000 claims description 9
- 230000015556 catabolic process Effects 0.000 claims description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 239000004745 nonwoven fabric Substances 0.000 claims description 8
- 239000000419 plant extract Substances 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 229940106189 ceramide Drugs 0.000 claims description 7
- 230000004069 differentiation Effects 0.000 claims description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 7
- 210000002510 keratinocyte Anatomy 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 6
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 6
- 102000016942 Elastin Human genes 0.000 claims description 6
- 108010014258 Elastin Proteins 0.000 claims description 6
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 6
- 210000001789 adipocyte Anatomy 0.000 claims description 6
- 150000001783 ceramides Chemical class 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 229920002549 elastin Polymers 0.000 claims description 6
- 239000000839 emulsion Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 229920002674 hyaluronan Polymers 0.000 claims description 6
- 229960003160 hyaluronic acid Drugs 0.000 claims description 6
- 230000001771 impaired effect Effects 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 230000037307 sensitive skin Effects 0.000 claims description 6
- 230000009759 skin aging Effects 0.000 claims description 6
- 238000013268 sustained release Methods 0.000 claims description 6
- 239000012730 sustained-release form Substances 0.000 claims description 6
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 5
- 241000222122 Candida albicans Species 0.000 claims description 5
- 206010007134 Candida infections Diseases 0.000 claims description 5
- 208000001840 Dandruff Diseases 0.000 claims description 5
- 206010013786 Dry skin Diseases 0.000 claims description 5
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 5
- 206010061304 Nail infection Diseases 0.000 claims description 5
- 208000012641 Pigmentation disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010048218 Xeroderma Diseases 0.000 claims description 5
- 206010000496 acne Diseases 0.000 claims description 5
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 201000003984 candidiasis Diseases 0.000 claims description 5
- 230000037336 dry skin Effects 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims description 5
- 230000003676 hair loss Effects 0.000 claims description 5
- 230000035876 healing Effects 0.000 claims description 5
- 206010021198 ichthyosis Diseases 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 239000003094 microcapsule Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 201000004700 rosacea Diseases 0.000 claims description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 4
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 4
- 239000004909 Moisturizer Substances 0.000 claims description 4
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 230000003712 anti-aging effect Effects 0.000 claims description 4
- 230000001153 anti-wrinkle effect Effects 0.000 claims description 4
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims description 4
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 4
- 239000000975 dye Substances 0.000 claims description 4
- 230000002500 effect on skin Effects 0.000 claims description 4
- 239000004744 fabric Substances 0.000 claims description 4
- 150000002191 fatty alcohols Chemical class 0.000 claims description 4
- 229940100242 glycol stearate Drugs 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 229920002521 macromolecule Polymers 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 230000001333 moisturizer Effects 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 230000008591 skin barrier function Effects 0.000 claims description 4
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 claims description 3
- 102000010637 Aquaporins Human genes 0.000 claims description 3
- 108010063290 Aquaporins Proteins 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- 102000004173 Cathepsin G Human genes 0.000 claims description 3
- 108090000617 Cathepsin G Proteins 0.000 claims description 3
- 229920000858 Cyclodextrin Polymers 0.000 claims description 3
- 102000004237 Decorin Human genes 0.000 claims description 3
- 108090000738 Decorin Proteins 0.000 claims description 3
- 102000000541 Defensins Human genes 0.000 claims description 3
- 108010002069 Defensins Proteins 0.000 claims description 3
- 102000016359 Fibronectins Human genes 0.000 claims description 3
- 108010067306 Fibronectins Proteins 0.000 claims description 3
- 108010028275 Leukocyte Elastase Proteins 0.000 claims description 3
- 102000016799 Leukocyte elastase Human genes 0.000 claims description 3
- 244000062730 Melissa officinalis Species 0.000 claims description 3
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 3
- 108010006519 Molecular Chaperones Proteins 0.000 claims description 3
- 102000008299 Nitric Oxide Synthase Human genes 0.000 claims description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 3
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 3
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 3
- 239000002280 amphoteric surfactant Substances 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 239000003899 bactericide agent Substances 0.000 claims description 3
- 239000000022 bacteriostatic agent Substances 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- 239000002738 chelating agent Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000000417 fungicide Substances 0.000 claims description 3
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- 208000024963 hair loss Diseases 0.000 claims description 3
- 239000013003 healing agent Substances 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 229920004918 nonoxynol-9 Polymers 0.000 claims description 3
- 229940087419 nonoxynol-9 Drugs 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 claims description 3
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 2
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 2
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 claims description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims description 2
- 241000195940 Bryophyta Species 0.000 claims description 2
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 2
- 208000035484 Cellulite Diseases 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 230000033616 DNA repair Effects 0.000 claims description 2
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004266 EU approved firming agent Substances 0.000 claims description 2
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims description 2
- UXDDRFCJKNROTO-UHFFFAOYSA-N Glycerol 1,2-diacetate Chemical compound CC(=O)OCC(CO)OC(C)=O UXDDRFCJKNROTO-UHFFFAOYSA-N 0.000 claims description 2
- 229930186217 Glycolipid Natural products 0.000 claims description 2
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 2
- 244000020551 Helianthus annuus Species 0.000 claims description 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims description 2
- 102000005741 Metalloproteases Human genes 0.000 claims description 2
- 108010006035 Metalloproteases Proteins 0.000 claims description 2
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 2
- 206010049752 Peau d'orange Diseases 0.000 claims description 2
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 2
- 208000003251 Pruritus Diseases 0.000 claims description 2
- 102000012479 Serine Proteases Human genes 0.000 claims description 2
- 108010022999 Serine Proteases Proteins 0.000 claims description 2
- 206010040925 Skin striae Diseases 0.000 claims description 2
- 229930182558 Sterol Natural products 0.000 claims description 2
- 208000031439 Striae Distensae Diseases 0.000 claims description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000003915 air pollution Methods 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003212 astringent agent Substances 0.000 claims description 2
- 229940076810 beta sitosterol Drugs 0.000 claims description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 2
- 239000007844 bleaching agent Substances 0.000 claims description 2
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 2
- 235000000431 campesterol Nutrition 0.000 claims description 2
- 239000003093 cationic surfactant Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 230000019522 cellular metabolic process Effects 0.000 claims description 2
- 230000004087 circulation Effects 0.000 claims description 2
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 229940097362 cyclodextrins Drugs 0.000 claims description 2
- 239000007854 depigmenting agent Substances 0.000 claims description 2
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims description 2
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims description 2
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 claims description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 230000007760 free radical scavenging Effects 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 150000002332 glycine derivatives Chemical class 0.000 claims description 2
- 150000002339 glycosphingolipids Chemical class 0.000 claims description 2
- 230000003793 hair pigmentation Effects 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 claims description 2
- 229940048848 lauryl glucoside Drugs 0.000 claims description 2
- 230000004130 lipolysis Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000008099 melanin synthesis Effects 0.000 claims description 2
- 230000004089 microcirculation Effects 0.000 claims description 2
- 238000000520 microinjection Methods 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000011929 mousse Nutrition 0.000 claims description 2
- 229940035363 muscle relaxants Drugs 0.000 claims description 2
- 239000003158 myorelaxant agent Substances 0.000 claims description 2
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 claims description 2
- 239000002088 nanocapsule Substances 0.000 claims description 2
- 239000002077 nanosphere Substances 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000002304 perfume Substances 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229950004354 phosphorylcholine Drugs 0.000 claims description 2
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000003711 photoprotective effect Effects 0.000 claims description 2
- 150000003038 phytosphingosines Chemical class 0.000 claims description 2
- 229940068065 phytosterols Drugs 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 230000000485 pigmenting effect Effects 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229940113124 polysorbate 60 Drugs 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 230000001012 protector Effects 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 2
- 229950005143 sitosterol Drugs 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 150000003432 sterols Chemical class 0.000 claims description 2
- 235000003702 sterols Nutrition 0.000 claims description 2
- 229940032091 stigmasterol Drugs 0.000 claims description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 claims description 2
- 235000016831 stigmasterol Nutrition 0.000 claims description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- FOUZISDNESEYLX-UHFFFAOYSA-N 2-(2-hydroxyethylazaniumyl)acetate Chemical compound OCCNCC(O)=O FOUZISDNESEYLX-UHFFFAOYSA-N 0.000 claims 1
- NPKLJZUIYWRNMV-UHFFFAOYSA-N 2-[decyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCC[N+](C)(C)CC([O-])=O NPKLJZUIYWRNMV-UHFFFAOYSA-N 0.000 claims 1
- TZGPACAKMCUCKX-UHFFFAOYSA-N 2-hydroxyacetamide Chemical compound NC(=O)CO TZGPACAKMCUCKX-UHFFFAOYSA-N 0.000 claims 1
- SGAQYTGHTWYTNW-UHFFFAOYSA-N NCCO.CCCCCCCCCCCC(N)=O Chemical compound NCCO.CCCCCCCCCCCC(N)=O SGAQYTGHTWYTNW-UHFFFAOYSA-N 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002250 absorbent Substances 0.000 claims 1
- 230000002745 absorbent Effects 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 238000004061 bleaching Methods 0.000 claims 1
- 229940031728 cocamidopropylamine oxide Drugs 0.000 claims 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 1
- IOBZMMXOKDNXPQ-UHFFFAOYSA-N dodecanamide;2-(2-hydroxyethylamino)ethanol Chemical compound OCCNCCO.CCCCCCCCCCCC(N)=O IOBZMMXOKDNXPQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008344 egg yolk phospholipid Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000007954 growth retardant Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229940040145 liniment Drugs 0.000 claims 1
- 229940055577 oleyl alcohol Drugs 0.000 claims 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044476 poloxamer 407 Drugs 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 238000005201 scrubbing Methods 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 119
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 26
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 22
- 230000000670 limiting effect Effects 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 18
- 239000010410 layer Substances 0.000 description 16
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 16
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 15
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- 235000011187 glycerol Nutrition 0.000 description 13
- 229960005150 glycerol Drugs 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- WSGCRSMLXFHGRM-DEVHWETNSA-N (2s)-2-[[(2s)-6-amino-2-[[(2s,3r)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxybutanoyl]amino]hexanoyl]amino]-3-hydroxypropanoic acid Chemical group CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O WSGCRSMLXFHGRM-DEVHWETNSA-N 0.000 description 9
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 description 9
- 229920002675 Polyoxyl Polymers 0.000 description 9
- 230000004075 alteration Effects 0.000 description 9
- JDRSMPFHFNXQRB-IBEHDNSVSA-N decyl glucoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O JDRSMPFHFNXQRB-IBEHDNSVSA-N 0.000 description 9
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 9
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 8
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 8
- 229960003415 propylparaben Drugs 0.000 description 8
- 239000000341 volatile oil Substances 0.000 description 8
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- JXPHIHWXMBYJAU-UHFFFAOYSA-N 7-methoxy-2,2-dimethyl-3,4-dihydrochromen-6-ol Chemical compound O1C(C)(C)CCC2=C1C=C(OC)C(O)=C2 JXPHIHWXMBYJAU-UHFFFAOYSA-N 0.000 description 7
- XPJVKCRENWUEJH-UHFFFAOYSA-N Isobutylparaben Chemical compound CC(C)COC(=O)C1=CC=C(O)C=C1 XPJVKCRENWUEJH-UHFFFAOYSA-N 0.000 description 7
- 229940067596 butylparaben Drugs 0.000 description 7
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 7
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 7
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 7
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 7
- 229960002216 methylparaben Drugs 0.000 description 7
- 229940060184 oil ingredients Drugs 0.000 description 7
- 229940093441 palmitoyl oligopeptide Drugs 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 229920001285 xanthan gum Polymers 0.000 description 7
- 239000000230 xanthan gum Substances 0.000 description 7
- 235000010493 xanthan gum Nutrition 0.000 description 7
- 229940082509 xanthan gum Drugs 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 6
- 108010073771 Soybean Proteins Proteins 0.000 description 6
- 241000209140 Triticum Species 0.000 description 6
- 235000021307 Triticum Nutrition 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 229920001296 polysiloxane Polymers 0.000 description 6
- 229940001941 soy protein Drugs 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- OFGVZFQUFJYSGS-CPDXTSBQSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s,3s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O OFGVZFQUFJYSGS-CPDXTSBQSA-N 0.000 description 5
- GKPMARPRXONRJX-BWJWTDLKSA-N (3s)-4-[[(2s,3s)-1-[[(2s)-1-amino-5-(carbamoylamino)-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-[[(2s)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid Chemical group NC(=O)NCCC[C@@H](C(N)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCCCN GKPMARPRXONRJX-BWJWTDLKSA-N 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 150000001345 alkine derivatives Chemical class 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 239000000084 colloidal system Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- ROTFCACGLKOUGI-JYJNAYRXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-(3-acetamidopropanoylamino)-3-(1h-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical group C([C@H](NC(=O)CCNC(=O)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 ROTFCACGLKOUGI-JYJNAYRXSA-N 0.000 description 4
- ZHUJMSMQIPIPTF-JMBSJVKXSA-N (2s)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-JMBSJVKXSA-N 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 244000144927 Aloe barbadensis Species 0.000 description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 235000011399 aloe vera Nutrition 0.000 description 4
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 239000002736 nonionic surfactant Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 description 3
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 3
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 244000133098 Echinacea angustifolia Species 0.000 description 3
- 244000194101 Ginkgo biloba Species 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 235000017309 Hypericum perforatum Nutrition 0.000 description 3
- 244000141009 Hypericum perforatum Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 244000042664 Matricaria chamomilla Species 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000519590 Pseudoalteromonas Species 0.000 description 3
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 3
- 241001529742 Rosmarinus Species 0.000 description 3
- 244000178231 Rosmarinus officinalis Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000017276 Salvia Nutrition 0.000 description 3
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 3
- 244000098338 Triticum aestivum Species 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 240000006365 Vitis vinifera Species 0.000 description 3
- 235000014787 Vitis vinifera Nutrition 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229960000271 arbutin Drugs 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- 210000000736 corneocyte Anatomy 0.000 description 3
- 239000008406 cosmetic ingredient Substances 0.000 description 3
- 229960001193 diclofenac sodium Drugs 0.000 description 3
- 229940117973 dimethylmethoxy chromanol Drugs 0.000 description 3
- NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 3
- 235000014134 echinacea Nutrition 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000002837 heart atrium Anatomy 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 description 3
- 229960004135 idebenone Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- 235000021283 resveratrol Nutrition 0.000 description 3
- 229940016667 resveratrol Drugs 0.000 description 3
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 3
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229940043375 1,5-pentanediol Drugs 0.000 description 2
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- AYPZAZPOYROADP-UHFFFAOYSA-N 2-(2-phenylethenyl)phenol Chemical class OC1=CC=CC=C1C=CC1=CC=CC=C1 AYPZAZPOYROADP-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- NCKMMSIFQUPKCK-UHFFFAOYSA-N 2-benzyl-4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1CC1=CC=CC=C1 NCKMMSIFQUPKCK-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- 244000082872 Alchemilla vulgaris Species 0.000 description 2
- 235000000008 Alchemilla vulgaris Nutrition 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000086254 Arnica montana Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MOZDKDIOPSPTBH-UHFFFAOYSA-N Benzyl parahydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OCC1=CC=CC=C1 MOZDKDIOPSPTBH-UHFFFAOYSA-N 0.000 description 2
- 240000001432 Calendula officinalis Species 0.000 description 2
- 235000005881 Calendula officinalis Nutrition 0.000 description 2
- 235000004032 Centella asiatica Nutrition 0.000 description 2
- 244000146462 Centella asiatica Species 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 2
- 229920002079 Ellagic acid Polymers 0.000 description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000195950 Equisetum arvense Species 0.000 description 2
- 239000005768 Equisetum arvense L. Substances 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 239000001263 FEMA 3042 Substances 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 2
- 108010023244 Lactoperoxidase Proteins 0.000 description 2
- 102000045576 Lactoperoxidases Human genes 0.000 description 2
- 241000219745 Lupinus Species 0.000 description 2
- 235000006770 Malva sylvestris Nutrition 0.000 description 2
- 240000002129 Malva sylvestris Species 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- 241000366182 Melaleuca alternifolia Species 0.000 description 2
- 235000004357 Mentha x piperita Nutrition 0.000 description 2
- 241001479543 Mentha x piperita Species 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 240000000783 Origanum majorana Species 0.000 description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 2
- 235000010582 Pisum sativum Nutrition 0.000 description 2
- 240000004713 Pisum sativum Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 241001050807 Rumex occidentalis Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000010841 Silybum marianum Nutrition 0.000 description 2
- 244000272459 Silybum marianum Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000177965 Vaccinium lamarckii Species 0.000 description 2
- 235000013473 Vaccinium lamarckii Nutrition 0.000 description 2
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- XMEDXTRRSJHOLZ-KRWDZBQOSA-N [(6as)-9-acetyloxy-1,10-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-2-yl] acetate Chemical compound CN1CCC2=CC(OC(C)=O)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC(C)=O)=C1 XMEDXTRRSJHOLZ-KRWDZBQOSA-N 0.000 description 2
- HSUGRPOJOBRRBK-SXBSVMRRSA-N acetic acid;(2s)-n-[(2s)-4-amino-1-(benzylamino)-1-oxobutan-2-yl]-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide Chemical compound CC(O)=O.CC(O)=O.N([C@@H](CCN)C(=O)NCC=1C=CC=CC=1)C(=O)[C@@H]1CCCN1C(=O)CCN HSUGRPOJOBRRBK-SXBSVMRRSA-N 0.000 description 2
- 108010006338 acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- LLEMOWNGBBNAJR-UHFFFAOYSA-N biphenyl-2-ol Chemical compound OC1=CC=CC=C1C1=CC=CC=C1 LLEMOWNGBBNAJR-UHFFFAOYSA-N 0.000 description 2
- 239000007978 cacodylate buffer Substances 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 235000021466 carotenoid Nutrition 0.000 description 2
- 150000001747 carotenoids Chemical class 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229960002852 ellagic acid Drugs 0.000 description 2
- 235000004132 ellagic acid Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- ZNJFBWYDHIGLCU-HWKXXFMVSA-N jasmonic acid Chemical compound CC\C=C/C[C@@H]1[C@@H](CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-HWKXXFMVSA-N 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 229940057428 lactoperoxidase Drugs 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 239000001771 mentha piperita Substances 0.000 description 2
- 150000002730 mercury Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000020748 rosemary extract Nutrition 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229940033123 tannic acid Drugs 0.000 description 2
- 229920002258 tannic acid Polymers 0.000 description 2
- 235000015523 tannic acid Nutrition 0.000 description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 2
- 208000009056 telangiectasis Diseases 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OGNHOGPWQTWKGQ-VGWMRTNUSA-N (2S)-5-amino-2-[[(2S)-1-[2-[[(2S)-5-amino-2-[[(2S)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoic acid Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 OGNHOGPWQTWKGQ-VGWMRTNUSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- SAVSLMGBKQKUAV-JYJNAYRXSA-N (2s)-2-[[(2s)-3-(4-hydroxyphenyl)-2-[[(2s)-3-methyl-2-[(2,2,2-trifluoroacetyl)amino]butanoyl]amino]propanoyl]amino]-3-methylbutanoic acid Chemical compound FC(F)(F)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CC1=CC=C(O)C=C1 SAVSLMGBKQKUAV-JYJNAYRXSA-N 0.000 description 1
- NTQVODZUQIATFS-WAUHAFJUSA-N (2s)-2-[[(2s)-6-amino-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]hexanoyl]amino]-3-methylbutanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O NTQVODZUQIATFS-WAUHAFJUSA-N 0.000 description 1
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 description 1
- PDQICKRFOKDJCH-INIZCTEOSA-N (2s)-6-amino-2-(dodecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCC(=O)N[C@H](C(O)=O)CCCCN PDQICKRFOKDJCH-INIZCTEOSA-N 0.000 description 1
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- XOMRRQXKHMYMOC-NRFANRHFSA-N (3s)-3-hexadecanoyloxy-4-(trimethylazaniumyl)butanoate Chemical compound CCCCCCCCCCCCCCCC(=O)O[C@@H](CC([O-])=O)C[N+](C)(C)C XOMRRQXKHMYMOC-NRFANRHFSA-N 0.000 description 1
- OKQBXIRUGKXBKP-AGQBKMEESA-N (3s,8s,9s,10r,13s,14s,16r,17r)-10,13-dimethyl-17-[(1s)-1-[(3s)-3-methyl-1,2,3,4-tetrahydropyridin-6-yl]ethyl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3,16-diol Chemical compound C1([C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)CC[C@H](O)CC5=CC[C@H]4[C@@H]3C[C@H]2O)C)C)=CC[C@H](C)CN1 OKQBXIRUGKXBKP-AGQBKMEESA-N 0.000 description 1
- AJLNZWYOJAWBCR-OOPVGHQCSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=C)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(N)=O AJLNZWYOJAWBCR-OOPVGHQCSA-N 0.000 description 1
- RJZNPROJTJSYLC-LLINQDLYSA-N (4s)-4-acetamido-5-[[(2s)-1-[[(2s)-1-[[(2s)-5-amino-1-[[(2s)-1-[[(2s)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-car Chemical compound OC(=O)CC[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O RJZNPROJTJSYLC-LLINQDLYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940031723 1,2-octanediol Drugs 0.000 description 1
- VUWCWMOCWKCZTA-UHFFFAOYSA-N 1,2-thiazol-4-one Chemical class O=C1CSN=C1 VUWCWMOCWKCZTA-UHFFFAOYSA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- KQBIYVMDUVJOIB-UHFFFAOYSA-N 1-(4-chlorophenyl)-1-[4-chloro-3-(trifluoromethyl)phenyl]urea Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1N(C(=O)N)C1=CC=C(Cl)C=C1 KQBIYVMDUVJOIB-UHFFFAOYSA-N 0.000 description 1
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- LGEZTMRIZWCDLW-UHFFFAOYSA-N 14-methylpentadecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC(C)C LGEZTMRIZWCDLW-UHFFFAOYSA-N 0.000 description 1
- VSHIRTNKIXRXMI-UHFFFAOYSA-N 2,2-dimethyl-1,3-oxazolidine Chemical compound CC1(C)NCCO1 VSHIRTNKIXRXMI-UHFFFAOYSA-N 0.000 description 1
- HDIFHQMREAYYJW-FMIVXFBMSA-N 2,3-dihydroxypropyl (e)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C\CCCCCCCC(=O)OCC(O)CO HDIFHQMREAYYJW-FMIVXFBMSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- PDHFSBXFZGYBIP-UHFFFAOYSA-N 2-[2-(2-hydroxyethylsulfanyl)ethylsulfanyl]ethanol Chemical compound OCCSCCSCCO PDHFSBXFZGYBIP-UHFFFAOYSA-N 0.000 description 1
- TYBHZVUFOINFDV-UHFFFAOYSA-N 2-bromo-6-[(3-bromo-5-chloro-2-hydroxyphenyl)methyl]-4-chlorophenol Chemical compound OC1=C(Br)C=C(Cl)C=C1CC1=CC(Cl)=CC(Br)=C1O TYBHZVUFOINFDV-UHFFFAOYSA-N 0.000 description 1
- OJIBJRXMHVZPLV-UHFFFAOYSA-N 2-methylpropyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(C)C OJIBJRXMHVZPLV-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- DQYSALLXMHVJAV-UHFFFAOYSA-M 3-heptyl-2-[(3-heptyl-4-methyl-1,3-thiazol-3-ium-2-yl)methylidene]-4-methyl-1,3-thiazole;iodide Chemical compound [I-].CCCCCCCN1C(C)=CS\C1=C\C1=[N+](CCCCCCC)C(C)=CS1 DQYSALLXMHVJAV-UHFFFAOYSA-M 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- YTKGAYFHUZTLCI-UHFFFAOYSA-N 3-hydroxy-2-iminopyrimidin-4-amine Chemical compound NC1=CC=NC(=N)N1O YTKGAYFHUZTLCI-UHFFFAOYSA-N 0.000 description 1
- NJLKZOZYTRRDBO-UHFFFAOYSA-N 3-iodopropyl n-butylcarbamate Chemical compound CCCCNC(=O)OCCCI NJLKZOZYTRRDBO-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- TZZGHGKTHXIOMN-UHFFFAOYSA-N 3-trimethoxysilyl-n-(3-trimethoxysilylpropyl)propan-1-amine Chemical compound CO[Si](OC)(OC)CCCNCCC[Si](OC)(OC)OC TZZGHGKTHXIOMN-UHFFFAOYSA-N 0.000 description 1
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-SNVBAGLBSA-N 4-Terpineol Natural products CC(C)[C@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-SNVBAGLBSA-N 0.000 description 1
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 229940046305 5-bromo-5-nitro-1,3-dioxane Drugs 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- DFTNLVRGBAMNHG-UHFFFAOYSA-N 6,6-dibromo-4,4-dichloro-2-[(2-hydroxyphenyl)methyl]cyclohex-2-en-1-ol Chemical compound ClC1(Cl)CC(Br)(Br)C(O)C(CC=2C(=CC=CC=2)O)=C1 DFTNLVRGBAMNHG-UHFFFAOYSA-N 0.000 description 1
- AMEMLELAMQEAIA-UHFFFAOYSA-N 6-(tert-butyl)thieno[3,2-d]pyrimidin-4(3H)-one Chemical compound N1C=NC(=O)C2=C1C=C(C(C)(C)C)S2 AMEMLELAMQEAIA-UHFFFAOYSA-N 0.000 description 1
- ZRCMGIXRGFOXNT-UHFFFAOYSA-N 7a-ethyl-1,3,5,7-tetrahydro-[1,3]oxazolo[3,4-c][1,3]oxazole Chemical compound C1OCN2COCC21CC ZRCMGIXRGFOXNT-UHFFFAOYSA-N 0.000 description 1
- 235000003934 Abelmoschus esculentus Nutrition 0.000 description 1
- 240000004507 Abelmoschus esculentus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 241000906543 Actaea racemosa Species 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 1
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 244000296825 Amygdalus nana Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241001647902 Arctostaphylos Species 0.000 description 1
- 235000004355 Artemisia lactiflora Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241001555820 Asarum maximum Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 235000010662 Bidens pilosa Nutrition 0.000 description 1
- 244000104272 Bidens pilosa Species 0.000 description 1
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- 241000705930 Broussonetia papyrifera Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- KNFLNGRLKALWRF-LDXSYGEZSA-N CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)CC1=CC=CC=C1 KNFLNGRLKALWRF-LDXSYGEZSA-N 0.000 description 1
- NXTGWOGJZSSREB-HJXLNUONSA-N C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 Chemical compound C[SiH2]O.O[C@H]1CN[C@H](C(O)=O)C1 NXTGWOGJZSSREB-HJXLNUONSA-N 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000002566 Capsicum Nutrition 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 240000001829 Catharanthus roseus Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 241000734239 Centipeda cunninghamii Species 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 240000009108 Chlorella vulgaris Species 0.000 description 1
- 235000007089 Chlorella vulgaris Nutrition 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- UDKCHVLMFQVBAA-UHFFFAOYSA-M Choline salicylate Chemical compound C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O UDKCHVLMFQVBAA-UHFFFAOYSA-M 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000182633 Cinchona succirubra Species 0.000 description 1
- 235000006768 Cinchona succirubra Nutrition 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 1
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 1
- 240000003527 Crinum asiaticum Species 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009852 Cucurbita pepo Nutrition 0.000 description 1
- 235000014375 Curcuma Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 244000019459 Cynara cardunculus Species 0.000 description 1
- 235000019106 Cynara scolymus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 244000281702 Dioscorea villosa Species 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 241000195634 Dunaliella Species 0.000 description 1
- 240000003826 Eichhornia crassipes Species 0.000 description 1
- 235000015489 Emblica officinalis Nutrition 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 240000000731 Fagus sylvatica Species 0.000 description 1
- 235000010099 Fagus sylvatica Nutrition 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 235000016622 Filipendula ulmaria Nutrition 0.000 description 1
- 244000308505 Filipendula ulmaria Species 0.000 description 1
- 241000195480 Fucus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930191978 Gibberellin Natural products 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 1
- 240000002024 Gossypium herbaceum Species 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 241000254191 Harpagophytum procumbens Species 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 description 1
- 101001126234 Homo sapiens Phospholipid phosphatase 3 Proteins 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 235000015265 Iris pallida Nutrition 0.000 description 1
- 240000004101 Iris pallida Species 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241001648859 Lilium candidum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 description 1
- 241001491705 Macrocystis pyrifera Species 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- 241000779599 Malpighia Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 235000010624 Medicago sativa Nutrition 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- 241000978725 Mimosa tenuiflora Species 0.000 description 1
- 241000865461 Mitracarpus Species 0.000 description 1
- 235000006721 Morus bombycis Nutrition 0.000 description 1
- 244000293610 Morus bombycis Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- RSYYQCDERUOEFI-JTQLQIEISA-N N-benzoyl-L-arginine Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)C1=CC=CC=C1 RSYYQCDERUOEFI-JTQLQIEISA-N 0.000 description 1
- IEZRNEGTKRQRFV-LFBNJJMOSA-N N-octadecanoyl-4-hydroxysphinganine Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)[C@H](O)CCCCCCCCCCCCCC IEZRNEGTKRQRFV-LFBNJJMOSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 240000006296 Naringi crenulata Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001398302 Padina pavonica Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000008114 Panicum miliaceum Species 0.000 description 1
- 235000007199 Panicum miliaceum Nutrition 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102100030450 Phospholipid phosphatase 3 Human genes 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 240000009120 Phyllanthus emblica Species 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 102100037132 Proteinase-activated receptor 2 Human genes 0.000 description 1
- 101710121435 Proteinase-activated receptor 2 Proteins 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241001478280 Rahnella Species 0.000 description 1
- 235000019057 Raphanus caudatus Nutrition 0.000 description 1
- 235000011380 Raphanus sativus Nutrition 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000009413 Ratibida columnifera Nutrition 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 235000000657 Rosa moschata Nutrition 0.000 description 1
- 244000018676 Rosa sp Species 0.000 description 1
- 240000004284 Rumex crispus Species 0.000 description 1
- 235000021501 Rumex crispus Nutrition 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 241000983746 Saccharina latissima Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001278097 Salix alba Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 235000002912 Salvia officinalis Nutrition 0.000 description 1
- 241000208829 Sambucus Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000580938 Sapindus Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000304432 Sedum sarmentosum Species 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 241000320380 Silybum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 240000006694 Stellaria media Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 244000103423 Tanacetum pathenium Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000009319 Terminalia catappa Nutrition 0.000 description 1
- 244000277583 Terminalia catappa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- JMSRDKIFVZVAMX-UHFFFAOYSA-N UNPD65971 Natural products OC1CC2C3CC=C4CC(O)CCC4(C)C3CCC2(C)C1C(C)C1=NCC(C)CC1 JMSRDKIFVZVAMX-UHFFFAOYSA-N 0.000 description 1
- 230000037338 UVA radiation Effects 0.000 description 1
- 241000683228 Uncaria guianensis Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000001978 Withania somnifera Nutrition 0.000 description 1
- 240000004482 Withania somnifera Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 description 1
- IPVNPUHVCZJVOI-VJSFXXLFSA-N [(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 IPVNPUHVCZJVOI-VJSFXXLFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 229940095094 acetyl hexapeptide-8 Drugs 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229940105017 achillea millefolium extract Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 229940070313 arctostaphylos uva-ursi leaf extract Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- TXVHTIQJNYSSKO-UHFFFAOYSA-N benzo[e]pyrene Chemical class C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229940034794 benzylparaben Drugs 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- XVBRCOKDZVQYAY-UHFFFAOYSA-N bronidox Chemical compound [O-][N+](=O)C1(Br)COCOC1 XVBRCOKDZVQYAY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DHAZIUXMHRHVMP-UHFFFAOYSA-N butyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCCC DHAZIUXMHRHVMP-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001390 capsicum minimum Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000011472 cat’s claw Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- 239000003467 chloride channel stimulating agent Substances 0.000 description 1
- VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical compound NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- MXOAEAUPQDYUQM-UHFFFAOYSA-N chlorphenesin Chemical compound OCC(O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-UHFFFAOYSA-N 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 235000005301 cimicifuga racemosa Nutrition 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 1
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- ODCCQUXDUXHSBP-UHFFFAOYSA-N decanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCC(O)=O ODCCQUXDUXHSBP-UHFFFAOYSA-N 0.000 description 1
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940090959 diacetyl boldine Drugs 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 229960004698 dichlorobenzyl alcohol Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- WSDISUOETYTPRL-UHFFFAOYSA-N dmdm hydantoin Chemical compound CC1(C)N(CO)C(=O)N(CO)C1=O WSDISUOETYTPRL-UHFFFAOYSA-N 0.000 description 1
- UWLPCYBIJSLGQO-UHFFFAOYSA-N dodecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCC(O)=O UWLPCYBIJSLGQO-UHFFFAOYSA-N 0.000 description 1
- QQQMUBLXDAFBRH-UHFFFAOYSA-N dodecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCOC(=O)C(C)O QQQMUBLXDAFBRH-UHFFFAOYSA-N 0.000 description 1
- 229960001859 domiphen bromide Drugs 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- MCEXMYNQJNYQLI-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate;hexyl 2-methylprop-2-enoate;2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C.CCCCCCOC(=O)C(C)=C.CC(=C)C(=O)OCCOCCOCCOC(=O)C(C)=C MCEXMYNQJNYQLI-UHFFFAOYSA-N 0.000 description 1
- 150000002171 ethylene diamines Chemical class 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940013688 formic acid Drugs 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 229940105040 geranium extract Drugs 0.000 description 1
- 239000003448 gibberellin Substances 0.000 description 1
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical class C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 150000002302 glucosamines Chemical class 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- ZFSXZJXLKAJIGS-UHFFFAOYSA-N halocarban Chemical compound C1=C(Cl)C(C(F)(F)F)=CC(NC(=O)NC=2C=CC(Cl)=CC=2)=C1 ZFSXZJXLKAJIGS-UHFFFAOYSA-N 0.000 description 1
- 229950006625 halocarban Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 description 1
- 229940078545 isocetyl stearate Drugs 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940033357 isopropyl laurate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940075495 isopropyl palmitate Drugs 0.000 description 1
- 229940089456 isopropyl stearate Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- ZNJFBWYDHIGLCU-UHFFFAOYSA-N jasmonic acid Natural products CCC=CCC1C(CC(O)=O)CCC1=O ZNJFBWYDHIGLCU-UHFFFAOYSA-N 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- UAWXGRJVZSAUSZ-UHFFFAOYSA-N licofelone Chemical compound OC(=O)CC=1N2CC(C)(C)CC2=C(C=2C=CC=CC=2)C=1C1=CC=C(Cl)C=C1 UAWXGRJVZSAUSZ-UHFFFAOYSA-N 0.000 description 1
- 229950003488 licofelone Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940013798 meclofenamate Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229940082473 melissa officinalis leaf extract Drugs 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- NALMPLUMOWIVJC-UHFFFAOYSA-N n,n,4-trimethylbenzeneamine oxide Chemical compound CC1=CC=C([N+](C)(C)[O-])C=C1 NALMPLUMOWIVJC-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- OXGBCSQEKCRCHN-UHFFFAOYSA-N octadecan-2-ol Chemical compound CCCCCCCCCCCCCCCCC(C)O OXGBCSQEKCRCHN-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 1
- 229950004864 olamine Drugs 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 235000010292 orthophenyl phenol Nutrition 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940070805 p-chloro-m-cresol Drugs 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940106026 phenoxyisopropanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- PETXWIMJICIQTQ-UHFFFAOYSA-N phenylmethoxymethanol Chemical compound OCOCC1=CC=CC=C1 PETXWIMJICIQTQ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 229940074543 primula veris extract Drugs 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- XEIOPEQGDSYOIH-MURFETPASA-N propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC(C)C XEIOPEQGDSYOIH-MURFETPASA-N 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- ZPWFUIUNWDIYCJ-UHFFFAOYSA-N propan-2-yl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C ZPWFUIUNWDIYCJ-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229940095574 propionic acid Drugs 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000013526 red clover Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- 229940094944 saccharide isomerate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000010671 sandalwood oil Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000037067 skin hydration Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 239000000264 sodium ferrocyanide Substances 0.000 description 1
- 235000012247 sodium ferrocyanide Nutrition 0.000 description 1
- GTSHREYGKSITGK-UHFFFAOYSA-N sodium ferrocyanide Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] GTSHREYGKSITGK-UHFFFAOYSA-N 0.000 description 1
- 229940032753 sodium iodate Drugs 0.000 description 1
- 239000011697 sodium iodate Substances 0.000 description 1
- 235000015281 sodium iodate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- QXVTUXGXNLUDJZ-AVUMXBEWSA-M sodium;[(3s,8s,9s,10r,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] sulfate Chemical compound [Na+].C1C=C2C[C@@H](OS([O-])(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 QXVTUXGXNLUDJZ-AVUMXBEWSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000020354 squash Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000001629 stilbenes Chemical class 0.000 description 1
- 235000021286 stilbenes Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 108010022069 sultilains Proteins 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229950010549 sutilains Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- BORJONZPSTVSFP-UHFFFAOYSA-N tetradecyl 2-hydroxypropanoate Chemical compound CCCCCCCCCCCCCCOC(=O)C(C)O BORJONZPSTVSFP-UHFFFAOYSA-N 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- SASUFNRGCZMRFD-JCUIILOWSA-N withanolide D Chemical compound C1C(C)=C(C)C(=O)O[C@H]1[C@](C)(O)[C@@H]1[C@@]2(C)CC[C@@H]3[C@@]4(C)C(=O)C=C[C@H](O)[C@@]54O[C@@H]5C[C@H]3[C@@H]2CC1 SASUFNRGCZMRFD-JCUIILOWSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229960001296 zinc oxide Drugs 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0291—Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición cosmética o dermofarmacéutica de micelas mixtas lípido-tensioactivo que se reconstituyen en el estrato córneo de la piel y su uso para el tratamiento y/o cuidado de la piel, pestañas, cabello y/o uñas.Cosmetic or dermopharmaceutical composition of mixed lipid-surfactant micelles that reconstitute in the stratum corneum of the skin and its use for treatment and / or care of the skin, eyelashes, hair and / or nails.
Description
Composición cosmética o dermofarmacéutica de micelas mixtas.Cosmetic or dermopharmaceutical composition of mixed micelles.
La presente invención se refiere a composiciones cosméticas o dermofarmacéuticas de micelas mixtas fosfolípido-tensioactivo donde las micelas mixtas se reconstituyen en liposomas mixtos en el estrato córneo de la piel encapsulando agua, y su uso para el tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías de la piel, pestañas, cabello y/o uñas asociadas a una excesiva pérdida de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas.The present invention relates to compositions Cosmetic or dermopharmaceuticals of mixed micelles phospholipid-surfactant where mixed micelles are reconstitute in mixed liposomes in the stratum corneum of the skin encapsulating water, and its use for the treatment and / or care of those conditions, disorders and / or pathologies of the skin, eyelashes, hair and / or nails associated with excessive water loss and / or the alteration of the barrier function of the skin, eyelashes, hair and / or nails.
El estrato córneo de la piel está formado por células planas finas, los corneocitos, separadas por capas lipídicas. Cada corneocito consta de un conjunto de filamentos de queratina dentro de una cubierta insoluble de proteínas. En la parte externa de esta cubierta, y químicamente unidas a las proteínas, se encuentran ceramidas de cadena larga que interaccionan con las capas lipídicas intercelulares, lo que en conjunto da una estructura hidrófoba. Adicionalmente, en el estrato córneo se encuentran tanto intracelular como extracelularmente moléculas identificadas como "factor natural de hidratación" (NMF) que por su naturaleza higroscópica sirven para retener el agua.The stratum corneum of the skin is formed by thin flat cells, corneocytes, separated by layers lipid Each corneocyte consists of a set of filaments of Keratin inside an insoluble protein shell. In the part outer of this shell, and chemically bound to proteins, it find long chain ceramides that interact with the layers intercellular lipids, which together gives a structure hydrophobic Additionally, in the stratum corneum are both intracellularly as extracellularly molecules identified as "natural hydration factor" (NMF) that by its nature Hygroscopic serve to retain water.
La función principal de esta estructura es la de barrera externa de la piel, y como barrera, esta estructura de corneocitos y lípidos sirve para regular la pérdida de agua transdérmica. La pérdida de agua transdérmica a través del estrato córneo de la piel es un hecho inherente al funcionamiento normal del estrato córneo, ya que es preciso hidratar las capas más externas del estrato córneo para mantener su flexibilidad, y es a través de estas capas por donde se produce la pérdida de agua. El hecho de tener que hidratar las capas más externas del estrato córneo genera un gradiente de agua dentro del estrato córneo, donde el porcentaje de agua varía desde menos del 20% desde las capas más externas hasta más del 40% en las capas más internas del estrato córneo ("Bioengineering of the Skin: Water and the Stratum Corneum", 1994, 3-12).The main function of this structure is that of the skin's external barrier, and as a barrier, this structure of corneocytes and lipids serves to regulate the loss of transdermal water. The loss of transdermal water through the stratum corneum of the skin is a fact inherent to the normal functioning of the stratum corneum, since it is necessary to hydrate the outermost layers of the stratum corneum to maintain its flexibility, and it is through these layers where Water loss occurs. Having to hydrate the outermost layers of the stratum corneum generates a water gradient within the stratum corneum, where the percentage of water varies from less than 20% from the outermost layers to more than 40% in the innermost layers of the stratum corneum (" Bioengineering of the Skin: Water and the Stratum Corneum ", 1994, 3-12).
Cuando la pérdida de agua transdérmica aumenta se produce una deshidratación de la piel que se refleja en una disminución de aproximadamente un 10% en el porcentaje de agua en las capas del estrato córneo y como resultado aparece una piel seca, con una menor flexibilidad y en la que es frecuente la descamación.When the loss of transdermal water increases there is a dehydration of the skin that is reflected in a decrease of approximately 10% in the percentage of water in the layers of the stratum corneum and as a result a dry skin appears, with less flexibility and in which the peeling.
Se ha demostrado que la perturbación de la estructura y composición del estrato córneo afecta a la función barrera que protege al organismo de las agresiones químicas, físicas y de la pérdida de agua transdérmica. Entre los factores que contribuyen a la deshidratación de la piel se encuentran la edad y las condiciones medioambientales como por ejemplo el frío, el calor y una baja humedad relativa.It has been shown that the disturbance of the structure and composition of the stratum corneum affects the function barrier that protects the body from chemical, physical aggressions and of the loss of transdermal water. Among the factors that contribute to skin dehydration are age and environmental conditions such as cold, heat and low relative humidity.
Para el restablecimiento de una piel hidratada
se conocen en el estado de la técnica diferentes estrategias de
recuperación de la piel seca como son la oclusión, la emoliencia y
la hidratación. La oclusión consiste en reducir la pérdida de agua a
través de la piel dañada y/o en proteger la piel sana mediante el
uso de aceites minerales o vegetales, lanolinas, siliconas, mezclas
artificiales de lípidos cutáneos o sustancias formadoras de
película. Sin embargo, inicialmente estas sustancias aumentan el
coeficiente de difusión del agua a través de la epidermis de modo
que al principio de la aplicación aumenta la velocidad de pérdida de
agua transdérmica. La emoliencia trata de aumentar la flexibilidad y
la suavidad del estrato córneo y la hidratación busca incrementar el
contenido hídrico del estrato
córneo.For the restoration of a hydrated skin, different recovery strategies for dry skin, such as occlusion, emolliency and hydration, are known in the state of the art. Occlusion consists of reducing water loss through damaged skin and / or protecting healthy skin through the use of mineral or vegetable oils, lanolines, silicones, artificial mixtures of skin lipids or film-forming substances. However, initially these substances increase the diffusion coefficient of water through the epidermis so that at the beginning of the application the rate of transdermal water loss increases. The emolliency tries to increase the flexibility and softness of the stratum corneum and hydration seeks to increase the water content of the stratum
horny.
Otro de los factores que contribuyen a la pérdida de agua transdérmica es el uso de tensioactivos en composiciones cosméticas o dermofarmacéuticas. Se conoce en el estado de la técnica que los tensioactivos se usan habitualmente en la solubilización de membranas, y en particular del estrato córneo, mediante la formación de micelas mixtas lípido-tensioactivo (Colloid Polym. Sci. 2001, 279, 909-915; Colloid Polym. Sci. 2002, 280, 352-357).Another factor that contributes to the loss of transdermal water is the use of surfactants in cosmetic or dermopharmaceutical compositions. It is known in the state of the art that surfactants are commonly used in the solubilization of membranes, and in particular of the stratum corneum, by the formation of mixed lipid-surfactant micelles ( Colloid Polym. Sci . 2001, 279, 909-915; Colloid Polym. Sci . 2002, 280, 352-357).
La proporción de ceramidas en los lípidos del estrato córneo desempeña un papel importante en la resistencia de estos lípidos a ser solubilizados por tensioactivos y por lo tanto en el mantenimiento de la estructura del estrato córneo (Colloids Surfaces A: Physicochem. Eng. Aspects 2000, 162, 131-140; International Journal of Pharmaceutics 1999, 187, 231-241). Así por ejemplo, el tratamiento del estrato córneo con octilglucósido conduce a una solubilización parcial del estrato córneo que aumenta con la concentración de octilglucósido hasta su concentración micelar crítica, donde la fracción solubilizada está constituida predominantemente por proteínas y en menor medida por lípidos, y que este tratamiento conduce a una disgregación del estrato córneo (Colloids Surfaces A: Physicochem. Eng. Aspects 1997, 123-124, 415-424).The proportion of ceramides in the lipids of the stratum corneum plays an important role in the resistance of these lipids to be solubilized by surfactants and therefore in the maintenance of the structure of the stratum corneum ( Colloids Surfaces A: Physicochem. Eng. Aspects 2000, 162, 131-140; International Journal of Pharmaceutics 1999, 187, 231-241). Thus, for example, the treatment of the stratum corneum with octylglucoside leads to a partial solubilization of the stratum corneum that increases with the concentration of octylglycoside to its critical micellar concentration, where the solubilized fraction is predominantly made up of proteins and to a lesser extent lipids, and that This treatment leads to a disintegration of the stratum corneum ( Colloids Surfaces A: Physicochem. Eng. Aspects 1997, 123-124, 415-424).
Si estas micelas mixtas lípido-tensioactivo se diluyen aumentando la concentración de lípidos, se forman vesículas de mayor tamaño donde el tamaño de las vesículas depende del tensioactivo utilizado (J. Phys. Chem. B 2001, 105 (40), 9879-9886). Se sabe también que esta disolución y formación de vesículas puede describirse como una serie de estructuras en equilibrio de vesículas, capas laminares y micelas mixtas donde los equilibrios se desplazan en función de la concentración relativa de tensioactivos y lípidos (Biochemistry 1988, 27, 1695-1703).If these mixed lipid-surfactant micelles are diluted by increasing the concentration of lipids, larger vesicles are formed where the size of the vesicles depends on the surfactant used ( J. Phys. Chem. B 2001, 105 ( 40 ), 9879-9886) . It is also known that this dissolution and formation of vesicles can be described as a series of equilibrium structures of vesicles, layered layers and mixed micelles where the equilibria shift depending on the relative concentration of surfactants and lipids ( Biochemistry 1988, 27, 1695- 1703).
Mientras que el tratamiento con tensioactivos se
ha utilizado para inducir cambios en el estrato córneo, la
aplicación tópica de liposomas de fosfolípidos se ha utilizado por
contra para mejorar las características cutáneas y como
estra-
tegia de protección del estrato córneo frente a un
posterior tratamiento con tensioactivos (Micron 2001, 32,
201-205).While surfactant treatment has been used to induce changes in the stratum corneum, topical application of phospholipid liposomes has been used to improve skin characteristics and as a stratum.
protection theory of the stratum corneum against subsequent treatment with surfactants ( Micron 2001, 32, 201-205).
Se conoce también en el estado de la técnica que el tratamiento de un estrato córneo con una baja cantidad de lípidos con liposomas formados con los lípidos del estrato córneo no recupera la estructura del estrato córneo y se observan cambios estructurales en las láminas lipídicas. Entre estos cambios se observa la formación de nuevas vesículas aisladas en las láminas lipídicas, y esta formación de vesículas podría estar asociada con una restauración de la estructura lipídica intercelular dañada (Colloids Surfaces A: Physicochem. Eng. Aspects 2001, 182, 35-42).It is also known in the state of the art that the treatment of a stratum corneum with a low amount of lipids with liposomes formed with the corneal stratum lipids does not recover the structure of the stratum corneum and structural changes are observed in the lipid sheets. Among these changes is the formation of new isolated vesicles in the lipid sheets, and this formation of vesicles could be associated with a restoration of the damaged intercellular lipid structure ( Colloids Surfaces A: Physicochem. Eng. Aspects 2001, 182, 35-42 ).
La solicitud internacional de patente WO 99/22703 A1 describe formulaciones de aplicación a mucosas que comprenden dispersiones de micelas de fosfolípidos que contienen un agente biológicamente activo, donde los fosfolípidos se adhieren a las mucosas y liberan el agente biológicamente activo de una manera sostenida a lo largo del tiempo. Estas formulaciones pueden contener además un tensioactivo. Sin embargo, no se indica en este documento que dichas dispersiones micelares puedan atravesar el estrato córneo si se aplican tópicamente a la piel.The international patent application WO 99/22703 A1 describes formulations for application to mucous membranes that comprise dispersions of phospholipid micelles containing a biologically active agent, where phospholipids adhere to the mucous membranes and release the biologically active agent in a way sustained over time. These formulations may contain also a surfactant. However, it is not indicated in this document. that said micellar dispersions can cross the stratum corneum if applied topically to the skin.
La solicitud de patente ES 2070778 A1 describe que cuando se añaden tensioactivos no-iónicos de balance hidrófilo-lipófilo (HLB) entre 10 y 12 en relaciones tensioactivo/fosfolípido del orden de 90/1 a 150/1 a composiciones cosméticas, no se produce la solubilización de liposomas de fosfolípidos en dichas composiciones cosméticas. En este documento se describe también la incorporación de principios activos y aditivos, si bien no se aporta información sobre la capacidad de penetración de los liposomas de la composición.Patent application ES 2070778 A1 describes that when non-ionic surfactants are added from hydrophilic-lipophilic balance (HLB) between 10 and 12 in surfactant / phospholipid ratios of the order of 90/1 to 150/1 a cosmetic compositions, solubilization of phospholipid liposomes in said cosmetic compositions. In This document also describes the incorporation of principles assets and additives, although no information is provided on the penetration capacity of the liposomes of the composition.
Por otro lado, en el estado de la técnica también se conoce que liposomas de fosfatidilcolina son capaces de penetrar en el estrato corneo por medio de algún mecanismo inducido por octilglucósido, ya que se observan vesículas de un tamaño de 190 nm dentro del estrato córneo, cuando la distancia intralaminar entre los lípidos del estrato córneo es tan sólo de 5-6 nm (Langmuir 2002, 18 (18), 7002-7008). En este mismo documento se hipotetiza que la presencia de estas vesículas de tamaño de 190 nm se debe a una reconstitución por dilución de micelas de fosfatidilcolina-octilglucósido en vesículas de fosfatidilcolina en la región lipídica intercelular del estrato córneo.On the other hand, it is also known in the state of the art that phosphatidylcholine liposomes are capable of penetrating the corneal stratum by means of some mechanism induced by octylglycoside, since vesicles of a size of 190 nm are observed within the stratum corneum, when the intralaminar distance between the lipids of the stratum corneum is only 5-6 nm ( Langmuir 2002, 18 (18), 7002-7008). In this same document it is hypothesized that the presence of these 190 nm size vesicles is due to a reconstitution by dilution of phosphatidylcholine-octylglycoside micelles in phosphatidylcholine vesicles in the intercellular lipid region of the stratum corneum.
Son numerosas las publicaciones en el estado de la técnica, como por ejemplo US 5128139 A que describen composiciones de aplicación tópica de dispersiones de liposomas unilaminares o multilaminares de fosfolípidos encapsulando activos cosméticos o dermofarmacéuticos. También se conoce el uso de liposomas que aumentan la hidratación de la piel (Cosmetic and Toiletries 1991, 106, 79-93). Sin embargo la capacidad de penetración de estos liposomas en la piel es muy baja y sólo un porcentaje muy bajo de liposomas realizan un efecto de oclusión por adhesión a las capas más externas de la piel.There are numerous publications in the state of the art, such as US 5128139 A that describe topically applied compositions of dispersions of unilamellar or multilamellar liposomes of phospholipids encapsulating cosmetic or dermopharmaceutical assets. The use of liposomes that increase skin hydration is also known ( Cosmetic and Toiletries 1991, 106, 79-93). However, the penetration capacity of these liposomes in the skin is very low and only a very low percentage of liposomes perform an occlusion effect by adhesion to the outermost layers of the skin.
Según el estado de la técnica anterior, se observa que los tensioactivos solubilizan membranas, y en particular la membrana del estrato córneo, y que de esta manera contribuyen a la pérdida de agua transdérmica. Además, el uso de los tensioactivos en la industria cosmética se encuentra ampliamente generalizado para solubilizar ingredientes cosméticos y/o aumentar la penetración de estos a través del estrato córneo, con lo cual su uso provoca un aumento de la pérdida de agua transdérmica.According to the prior art, it is note that surfactants solubilize membranes, and in particular the stratum corneum membrane, and that in this way contribute to The loss of transdermal water. In addition, the use of surfactants in the cosmetic industry it is widely widespread for solubilize cosmetic ingredients and / or increase the penetration of these through the stratum corneum, with which its use causes a Increase in transdermal water loss.
Así pues, existe la necesidad de encontrar composiciones cosméticas que comprendan tensioactivos que no contribuyan a aumentar la pérdida de agua transdérmica, no disminuyan la función barrera de la piel, y que faciliten la penetración de liposomas y/o ingredientes cosméticos o dermofarmacéuticos a través del estrato córneo.So, there is a need to find cosmetic compositions comprising surfactants that do not contribute to increase the loss of transdermal water, not reduce the skin's barrier function, and facilitate penetration of liposomes and / or cosmetic ingredients or Dermopharmaceuticals through the stratum corneum.
La presente invención aporta una solución al problema arriba mencionado. Sorprendentemente se ha descubierto en la presente invención una composición cosmética o dermofarmacéutica que comprende una dispersión de micelas mixtas fosfolípido-tensioactivo y el uso de esta composición para el tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías de la piel, pestañas, cabello y/o uñas asociadas a una excesiva pérdida de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas.The present invention provides a solution to the problem mentioned above. Surprisingly it has been discovered in the present invention a cosmetic or dermopharmaceutical composition comprising a dispersion of mixed micelles phospholipid-surfactant and the use of this composition for the treatment and / or care of those conditions, disorders and / or pathologies of the skin, eyelashes, hair and / or nails associated with excessive loss of water and / or alteration of the Barrier function of the skin, eyelashes, hair and / or nails.
Por lo tanto un primer aspecto de la presente invención se refiere a una composición cosmética o dermofarmacéutica que comprende una dispersión de micelas mixtas fosfolípido-tensioactivo, donde estas micelas mixtas se reconstituyen en liposomas en el estrato córneo de la piel encapsulando agua.Therefore a first aspect of the present invention refers to a cosmetic or dermopharmaceutical composition comprising a dispersion of mixed micelles phospholipid-surfactant, where these mixed micelles they are reconstituted in liposomes in the stratum corneum of the skin encapsulating water
El término "micela mixta" se refiere en la presente invención a un agregado aproximadamente esférico formado por una monocapa homogénea de uno o más tensioactivos y de uno o más fosfolípidos en un disolvente polar donde las regiones polares de los tensioactivos y de los fosfolípidos se orientan hacia el disolvente y constituyen la cara externa de la micela, mientras que las regiones apolares de los tensioactivos y de los fosfolípidos forman la cara interna de la micela.The term "mixed micelle" refers to the present invention to an approximately spherical aggregate formed by a homogeneous monolayer of one or more surfactants and one or more phospholipids in a polar solvent where the polar regions of surfactants and phospholipids are oriented towards the solvent and constitute the outer face of the micelle while apolar regions of surfactants and phospholipids They form the inner face of the micelle.
El término "liposoma" se refiere en la presente invención a un agregado aproximadamente esférico formado por al menos una capa doble o bicapa de al menos un fosfolípido donde las capas se encuentran muy próximas y las regiones apolares de cada capa se orientan hacia las regiones apolares de la otra capa lipídica, y de esta manera las regiones polares de los fosfolípidos forman la cara interna y externa de la doble capa o bicapa. Los liposomas de la presente invención pueden tener una sola bicapa y se estructuran como liposomas unilaminares, o bien pueden tener de 2 a 6 bicapas, concéntricas o no, de lípidos, preferentemente de 2 a 4 bicapas concéntricas, y entonces se organizan como liposomas multilaminares tipo cebolla, o bien pueden tener de 2 a 6 bicapas y se organizan como liposomas unilaminares que comprenden de 1 a 5 liposomas unilaminares más pequeños.The term "liposome" refers to the present invention to an approximately spherical aggregate formed by at least a double or bilayer layer of at least one phospholipid where the layers are very close and the apolar regions of each layer are oriented towards the apolar regions of the other layer lipid, and thus the polar regions of phospholipids they form the inner and outer face of the double layer or bilayer. The Liposomes of the present invention may have a single bilayer and be they structure as unilamellar liposomes, or they can have from 2 to 6 bilayers, concentric or not, of lipids, preferably 2 to 4 concentric bilayers, and then they are organized as liposomes multilaminar onion type, or they can have 2 to 6 bilayers and they are organized as unilamellar liposomes that comprise 1 to 5 smaller unilamellar liposomes.
En una realización particular, los liposomas son liposomas mixtos formados por moléculas de uno o más lípidos y de uno o más tensioactivos distribuidos homogéneamente en cada una de las capas dobles o bicapas y con las estructuras descritas anteriormente para los liposomas.In a particular embodiment, the liposomes are mixed liposomes formed by molecules of one or more lipids and of one or more surfactants homogeneously distributed in each of double layers or bilayers and with the structures described formerly for liposomes.
En una realización particular, el tensioactivo de las micelas mixtas fosfolípido- tensioactivo se selecciona del grupo formado por los tensioactivos no-iónicos, tensioactivos anfóteros, tensioactivos aniónicos, tensioactivos catiónicos y sus mezclas. Preferentemente los tensioactivos de la composición de la presente invención son tensioactivos no-iónicos y/o tensioactivos anfóteros, más preferentemente se seleccionan del grupo formado por alquilglicósidos con un grupo alquilo que tiene de 6 a 24 átomos de carbono, alquilmaltósidos con un grupo alquilo que tiene de 6 a 24 átomos de carbono, alquilfenoles etoxilados con un grupo alquilo que tiene de 6 a 24 átomos de carbono y de 5 a 30 unidades de óxido de etileno, éteres de alquilfenilpolioxietileno con un grupo alquilo que tiene de 6 a 24 átomos de carbono, alcoholes grasos saturados o insaturados con un grupo alquilo que tiene de 8 a 24 átomos de carbono, poloxámeros, polisorbatos, ésteres de sorbitano, ésteres de ácidos grasos de polietilenglicol, aceites de ricino, éteres de alcoholes grasos y polioxietileno, alcanolamidas de ácidos grasos, óxidos de aminas, alquilbetaínas con un grupo alquilo que tiene de 6 a 24 átomos de carbono, acilamidobetaínas, alquilsulfobetaínas con un grupo alquilo que tiene de 6 a 24 átomos de carbono, derivados de glicina, digitonina y sus mezclas. Más preferentemente se seleccionan del grupo formado por octilglucósido, decilglucósido, laurilglucósido, octilfructósido, dodecilmaltósido, decilmaltósido, nonoxinol-9, polietilenglicol p-(1,1,3,3-tetrametilbutil)feniléter, palmitilalcohol, oleilalcohol, poloxámero 188, poloxámero 407, polisorbato 20, polisorbato 60, polisorbato 80, estearato de polietilenglicol 40, estearato de polietilenglicol 50, estearato de polietilenglicol 100, polioxietilenesteariléter, polioxietilenlauriléter, cocamida monoetanolamina, cocamida dietanolamina, cocamida trietanolamina, lauramida dietanolamina, lauramida monoetanolamina, óxido de cocamidopropilamina, decilbetaína, dodecilbetaína, tetradecilbetaína, cocoilbetaína, cocamidopropilbetaína, cocamidopropil hidroxisultaína, N-2-hidroxietilglicinato de cocoilamidoetilo y N-2-hidroxietilcarboxiglicinato de cocoilamidoetilo y sus mezclas.In a particular embodiment, the phospholipid surfactant mixed micelles surfactant is selected from the group consisting of non-ionic surfactants, amphoteric surfactants, anionic surfactants, cationic surfactants and mixtures thereof. Preferably the surfactants of the composition of the present invention are non-ionic surfactants and / or amphoteric surfactants, more preferably they are selected from the group consisting of alkyl glycosides with an alkyl group having from 6 to 24 carbon atoms, alkyl maltosides with an alkyl group which it has from 6 to 24 carbon atoms, ethoxylated alkylphenols with an alkyl group having from 6 to 24 carbon atoms and from 5 to 30 units of ethylene oxide, alkylphenylpolyoxyethylene ethers with an alkyl group having from 6 to 24 atoms of carbon, saturated or unsaturated fatty alcohols with an alkyl group having from 8 to 24 carbon atoms, poloxamers, polysorbates, sorbitan esters, polyethylene glycol fatty acid esters, castor oils, fatty alcohol and polyoxyethylene ethers, acid alkanolamides fatty, amine oxides, alkyl betaines with an alkyl group having 6 to 24 carbon atoms, acylamido betaines, alkyl ilsulfobetains with an alkyl group having 6 to 24 carbon atoms, derivatives of glycine, digitonin and mixtures thereof. More preferably, they are selected from the group consisting of octylglucoside, decylglucoside, laurylglucoside, octylfructoside, dodecylmaltoside, decylmaltoside, nonoxynol-9, polyethylene glycol p - (1,1,3,3-tetramethylbutyl) phenyl ether, palmityl alcohol, polyoxyl, polyoxyl, polyoxyl, polyoxyl, polyoxyl, polyoxyl, polyoxyl, polyoxyl, polyoxyl, alcohol polysorbate 20, polysorbate 60, polysorbate 80, polyethylene glycol stearate 40, polyethylene glycol stearate 50, polyethylene glycol 100 stearate, polyoxyethylene stearyl ether, polyoxyethylene lauryl ether, cocamide monoethanolamine, cocamide diethanolamine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine amine, cocamidaelamine, amine, amine , tetradecilbetaína, cocoilbetaína, cocamidopropyl betaine, cocamidopropyl hydroxysultaine, N -2-hidroxietilglicinato of cocoilamidoetilo and N -2-hidroxietilcarboxiglicinato of cocoilamidoetilo and mixtures thereof.
En otra realización particular, el fosfolípido de las micelas de la composición de la presente invención es un fosfoglicérido natural o sintético y preferentemente se selecciona del grupo formado por fosfatidilserina, fosfatidilinositol, fosfatidiletanolamina, fosfatidilcolina, ácido fosfatídico, fosfatidilglicerol, difosfatidilglicerol, fosforilcolina, cardiolipina, sus ésteres de ácidos grasos, productos de hidrogenación y sus mezclas, como por ejemplo y sin sentido limitativo lecitinas de huevo, soja o girasol. Entre los ácidos grasos se encuentran por ejemplo y sin sentido limitativo los ácidos esteárico, palmítico, oleico, mirístico, laúrico y todos aquellos ácidos grasos saturados o insaturados conocidos en el estado de la técnica.In another particular embodiment, the phospholipid of the micelles of the composition of the present invention is a natural or synthetic phosphoglyceride and preferably selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylethanolamine, phosphatidylcholine, phosphatidic acid, phosphatidylglycerol, diphosphatidylglycerol, phosphorylcholine, Cardiolipin, its fatty acid esters, products of hydrogenation and mixtures thereof, such as for example and meaningless Limiting egg, soy or sunflower lecithins. Between acids fatty acids are found for example and without limiting sense acids stearic, palmitic, oleic, myristic, lauric and all those saturated or unsaturated fatty acids known in the state of the technique.
En otra realización particular, la relación en peso tensioactivo/fosfolípido en las micelas de la composición de la presente invención varía entre un 150/1 y un 1/1, preferentemente entre un 50/1 y un 2/1, y más preferentemente entre un 10/1 y un 4/1.In another particular embodiment, the relationship in surfactant / phospholipid weight in the micelles of the composition of the The present invention varies between 150/1 and 1/1, preferably between 50/1 and 2/1, and more preferably between 10/1 and a 4/1.
En otra realización particular, el diámetro de las micelas de la composición de la presente invención es inferior a 35 nm, preferentemente es inferior a 20 nm, y más preferentemente es inferior a 10 nm.In another particular embodiment, the diameter of The micelles of the composition of the present invention is less than 35 nm, preferably it is less than 20 nm, and more preferably it is less than 10 nm.
En otra realización particular, el diámetro de los liposomas reconstituidos varía entre 80 nm y 700 nm, preferentemente entre 120 nm y 350 nm, y más preferentemente entre 160 nm y 250 nm.In another particular embodiment, the diameter of The reconstituted liposomes vary between 80 nm and 700 nm, preferably between 120 nm and 350 nm, and more preferably between 160 nm and 250 nm.
En otra realización particular, el porcentaje de agua encapsulada en los liposomas reconstituidos varía entre un 5% y un 95% en peso respecto al peso total del liposoma, preferentemente entre un 15% y un 75% en peso, y más preferentemente entre un 30% y un 60% en peso.In another particular embodiment, the percentage of Water encapsulated in the reconstituted liposomes varies between 5% and 95% by weight with respect to the total weight of the liposome, preferably between 15% and 75% by weight, and more preferably between 30% and 60% by weight.
En otra realización particular, las micelas mixtas de la composición de la invención comprenden adicionalmente al menos un lípido, seleccionado del grupo formado por glicéridos, esteroles, prenoles, glicolípidos, ceramidas, glicoesfingolípidos, ácidos grasos, y sus mezclas, como por ejemplo y sin sentido limitativo colesterol, campesterol, estigmasterol, beta-sitosterol, ergosterol, fitosteroles, triglicéridos, 1,2-diacilglicerol, fitoesfingosinas, estearilamina o sus mezclas.In another particular embodiment, the micelles mixed of the composition of the invention further comprise at least one lipid, selected from the group consisting of glycerides, sterols, prenoles, glycolipids, ceramides, glycosphingolipids, fatty acids, and mixtures thereof, such as for example and meaningless limiting cholesterol, campesterol, stigmasterol, beta-sitosterol, ergosterol, phytosterols, triglycerides, 1,2-diacylglycerol, phytosphingosines, Stearylamine or mixtures thereof.
En otra realización particular, el disolvente de la composición cosmética o dermofarmacéutica de la presente invención es cualquier disolvente o mezcla de disolventes convencionales cosmética o dermofarmacéuticamente aceptables tales como por ejemplo y sin sentido limitativo agua, etanol, propanol, isopropanol, propilenglicol, glicerina, butilenglicol, hexilenglicol, etoxidiglicol, polietilenglicol y/o una combinación de los mismos.In another particular embodiment, the solvent of the cosmetic or dermopharmaceutical composition of the present invention is any solvent or solvent mixture conventional cosmetic or dermopharmaceutically acceptable such such as and without limitation water, ethanol, propanol, isopropanol, propylene glycol, glycerin, butylene glycol, hexylene glycol, ethoxyglycol, polyethylene glycol and / or a combination thereof.
Es conocido por el estado de la técnica, que la solubilidad de las micelas mixtas fosfolípido-tensioactivo es diferente para cada disolvente variando en función de la naturaleza del fosfolípido y de la concentración micelar crítica del tensioactivo en el disolvente o mezcla de disolvente. Por lo tanto, la concentración máxima de micelas mixtas dispersas en las composiciones cosméticas o dermofarmacéuticas de la presente invención depende de los factores anteriores.It is known for the state of the art, that the solubility of mixed micelles phospholipid-surfactant is different for each solvent varying depending on the nature of the phospholipid and of the critical micellar concentration of the surfactant in the solvent or solvent mixture. Therefore, the maximum concentration of mixed micelles dispersed in cosmetic compositions or Dermopharmaceuticals of the present invention depend on the factors previous.
En otra realización particular, la composición cosmética o dermofarmacéutica de la invención comprende adicionalmente una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un adyuvante cosmético o dermofarmacéutico. El adyuvante cosmético o dermofarmacéutico puede estar disperso en la composición o bien encapsulado en las micelas mixtas, y una vez reconstituidas en liposomas el adyuvante cosmético o dermofarmacéutico puede quedar fuera del liposoma, o bien en el interior del liposoma en la bicapa de lípidos y/o en el núcleo polar del liposoma. Entre los adyuvantes cosméticos o dermofarmacéuticos contenidos en las micelas mixtas de la composición de la invención se encuentran los adyuvantes comúnmente empleados en composiciones para el tratamiento y/o cuidado de la piel, pestañas, cabello y/o uñas tales como por ejemplo y sin sentido limitativo, acondicionadores de la piel como por ejemplo adyuvantes cosméticos o dermofarmacéuticos que recuperan y/o mantienen la función barrera de la piel, enzimas epidérmicas hidrolíticas, alfahidroxiácidos, betahidroxiácidos, agentes descamantes, agentes estimuladores o inhibidores de la síntesis de melanina, agentes blanqueantes o despigmentantes, agentes propigmentantes, agentes autobronceantes, agentes antienvejecimiento, agentes inhibidores de la NO-sintasa, disolventes orgánicos, propelentes líquidos, vitaminas, pigmentos o colorantes, tintes, polímeros gelificantes, espesantes, suavizantes, agentes antiarrugas, agentes dermorelajantes, agentes capaces de disminuir o tratar las bolsas bajo los ojos, agentes exfoliantes, agentes anti-prurito, agentes para el tratamiento y/o cuidado de pieles sensibles, agentes reafirmantes, agentes astringentes, agentes estimuladores de la lipólisis, agentes anticelulíticos, agentes calmantes, agentes antiinflamatorios, agentes analgésicos, agentes que actúen sobre el metabolismo de las células, agentes destinados a mejorar la unión dermis-epidermis, agentes inductores del crecimiento del cabello, agentes inhibidores o retardantes del crecimiento del cabello, relajantes musculares, conservantes, perfumes, absorbentes del olor, agentes quelantes, extractos vegetales, aceites esenciales, extractos marinos, agentes provenientes de un procedimiento de biofermentación, sales minerales, extractos celulares y filtros solares (agentes fotoprotectores de naturaleza orgánica o mineral activos contra los rayos ultravioleta A y/o B) entre otros y/o sus mezclas, siempre que sean física y químicamente compatibles con el resto de componentes de la composición y en especial con las micelas mixtas fosfolípido-tensioactivo contenidas en la composición de la presente invención. Los adyuvantes cosméticos o dermofarmacéuticos que recuperan y/o mantienen la función barrera de la piel son por ejemplo humectantes, sustancias que retienen la humedad, hidratantes, emolientes, agentes emulsionantes, agentes estimuladores de la síntesis de lípidos y componentes del estrato córneo (ceramidas, ácidos grasos, proteínas, etc.), agentes inhibidores de la 5\alpha-reductasa, agentes inhibidores de lisil- y/o prolil-hidroxilasa, agentes antioxidantes, agentes capturadores de radicales libres y/o anti-contaminación atmosférica, agentes anti-glicación, agentes antimicrobianos, agentes fungicidas, agentes fungistáticos, agentes bactericidas, agentes bacteriostáticos, agentes estimuladores de la síntesis de macromoléculas dérmicas o epidérmicas y/o capaces de inhibir o prevenir su degradación, como por ejemplo y sin sentido limitativo agentes estimuladores de la síntesis de colágeno, agentes estimuladores de la síntesis de elastina, agentes estimuladores de la síntesis de decorina, agentes estimuladores de la síntesis de laminina, agentes estimuladores de la síntesis de defensinas, agentes estimuladores de la síntesis de chaperonas, agentes estimuladores de la síntesis de ácido hialurónico, agentes estimuladores de la síntesis de aquaporinas, agentes estimuladores de la síntesis de fibronectina, agentes inhibidores de metaloproteasas de matriz, agentes inhibidores de la degradación de colágeno, agentes inhibidores de la degradación de elastina, agentes inhibidores de proteasas de serina como leucocito elastasa o catepsina G, agentes estimuladores de la proliferación de fibroblastos, agentes estimuladores de la proliferación de queratinocitos, agentes estimuladores de la proliferación de adipocitos, agentes estimuladores de la diferenciación de queratinocitos, agentes estimuladores de la diferenciación de adipocitos, agentes estimuladores de la angiogénesis, agentes estimuladores de la síntesis de glicosaminoglicanos, agentes reparadores del ADN, agentes protectores del ADN, agentes anti-estrías, agentes reguladores de la producción de sebo, agentes estimuladores de la cicatrización, agentes coadyuvantes de la cicatrización, agentes reepitelizantes, factores de crecimiento de citoquinas, agentes que actúen sobre la circulación capilar y/o la microcirculación y/o sus mezclas. Asimismo, la naturaleza de dichos adyuvantes adicionales no debe alterar de manera inaceptable los beneficios de la composición de micelas mixtas de la presente invención. La naturaleza de dichos adyuvantes adicionales puede ser sintética o de origen natural, como por ejemplo extractos vegetales, o provenir de un procedimiento de biofermentación. Ejemplos adicionales pueden encontrarse descritos en CTFA Cosmetic Ingredient Handbook, Eleventh Edition 2006.In another particular embodiment, the cosmetic or dermopharmaceutical composition of the invention further comprises a cosmetic or dermopharmaceutically effective amount of at least one cosmetic or dermopharmaceutical adjuvant. The cosmetic or dermopharmaceutical adjuvant can be dispersed in the composition or encapsulated in the mixed micelles, and once the cosmetic or dermopharmaceutical adjuvant can be reconstituted in liposomes, it can be left outside the liposome, or inside the liposome in the lipid bilayer and / or in the polar nucleus of the liposome. Among the cosmetic or dermopharmaceutical adjuvants contained in the mixed micelles of the composition of the invention are the adjuvants commonly employed in compositions for the treatment and / or care of skin, eyelashes, hair and / or nails such as for example and nonsense limiting, skin conditioners such as cosmetic or dermopharmaceutical adjuvants that recover and / or maintain the skin's barrier function, hydrolytic epidermal enzymes, alphahydroxy acids, betahydroxy acids, descaling agents, stimulating agents or inhibitors of melanin synthesis, bleaching agents or depigmenting agents, pro-pigmenting agents, self-tanning agents, anti-aging agents, NO-synthase inhibitors, organic solvents, liquid propellants, vitamins, pigments or dyes, dyes, gelling polymers, thickeners, softeners, anti-wrinkle agents, dermaking agents, agents capable of reducing ot rat bags under the eyes, exfoliating agents, anti-itching agents, agents for the treatment and / or care of sensitive skin, firming agents, astringent agents, lipolysis stimulating agents, anti-cellulite agents, soothing agents, anti-inflammatory agents, analgesic agents , agents that act on the metabolism of cells, agents intended to improve the dermis-epidermis junction, agents that induce hair growth, agents that inhibit or retard hair growth, muscle relaxants, preservatives, perfumes, odor absorbers, chelating agents , plant extracts, essential oils, marine extracts, agents from a biofermentation process, mineral salts, cellular extracts and sunscreens (photoprotective agents of organic or mineral nature active against ultraviolet rays A and / or B) among others and / or their mixtures, provided they are physically and chemically compatible with the other components of the composition and especially with the phospholipid-surfactant mixed micelles contained in the composition of the present invention. Cosmetic or dermopharmaceutical adjuvants that recover and / or maintain the skin's barrier function are for example moisturizers, moisture-retaining substances, moisturizers, emollients, emulsifying agents, lipid synthesis stimulating agents and stratum corneum components (ceramides, fatty acids, proteins, etc.), 5α-reductase inhibitors, lysyl- and / or prolyl hydroxylase inhibitors, antioxidant agents, free radical scavenging agents and / or atmospheric anti-pollution agents, anti- glycation, antimicrobial agents, fungicidal agents, fungistatic agents, bactericidal agents, bacteriostatic agents, agents that stimulate the synthesis of dermal or epidermal macromolecules and / or capable of inhibiting or preventing their degradation, such as, for example and without limiting sense, agents that stimulate synthesis of collagen, elastin synthesis stimulating agents, l stimulating agents to decorin synthesis, laminin synthesis stimulating agents, defensin synthesis stimulating agents, chaperone synthesis stimulating agents, hyaluronic acid synthesis stimulating agents, aquaporin synthesis stimulating agents, stimulating agents fibronectin synthesis, matrix metalloprotease inhibitors, collagen degradation inhibitors, elastin degradation inhibitors, serine protease inhibitors such as leukocyte elastase or cathepsin G, fibroblast proliferation stimulating agents, stimulating agents of keratinocyte proliferation, adipocyte proliferation stimulating agents, keratinocyte differentiation stimulating agents, adipocyte differentiation stimulating agents, angiogenesis stimulating agents, glycosaminoglycan synthesis stimulating agents, age DNA repair agents, DNA protective agents, anti-stretch marks, sebum production regulators, healing agents, healing agents, re-epithelizing agents, cytokine growth factors, agents acting on the circulation capillary and / or microcirculation and / or mixtures thereof. Also, the nature of said additional adjuvants should not unacceptably alter the benefits of the mixed micelle composition of the present invention. The nature of said additional adjuvants can be synthetic or of natural origin, such as plant extracts, or come from a biofermentation process. Additional examples can be found described in CTFA Cosmetic Ingredient Handbook , Eleventh Edition 2006.
Otra realización de la presente invención se refiere a una composición cosmética o dermofarmacéutica de micelas mixtas que comprende una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto seleccionado del grupo de los adyuvantes cosméticos o dermofarmacéuticos que recuperan y/o mantienen la función barrera de la piel formado por humectantes, sustancias que retienen la humedad, hidratantes, emolientes, agentes emulsionantes y sus mezclas, como por ejemplo y sin sentido limitativo, glicerina, pentilenglicol, propilenglicol, Glycereth-26, Sorbeth-30, pantenol, trehalosa y sus derivados, ácido hialurónico y sus derivados, ácido piroglutámico y sus derivados, serina, prolina, glutamato, arginina, urea, creatina, glucosaminas, ácido láctico, lactato de laurilo, lactato de miristilo, poligliceril acrilato, ectoína y sus derivados, quitosano, N-(2-hidroxietil)acetamida, sacárido isomerato, sorbitol, pentaeritritol, inositol, xilitol, 2-pirrolidona-5-carboxilato de sodio, ácido N-lauroil-pirrolidonacarboxílico, N-lauroil-L-lisina, N-alfa-benzoil-L-arginina, colágeno soluble, dibutilftalato, gelatina, alcohol esteárico, gliceril monoricinoleato, gliceril monoestearato, propan-1,2-diol, butan-1,3-diol, aceite de visón, alcohol cetílico, isoestearato de isopropilo, ácido esteárico, palmitato de isobutilo, estearato de isocetilo, alcohol oléico, laurato de isopropilo, laurato de hexilo, oleato de decilo, octadecan-2-ol, alcohol isocetílico, palmitato de cetilo, dimetilpolisiloxano, sebacato de di-n-butilo, miristato de isopropilo, palmitato de isopropilo, estearato de isopropilo, estearato de butilo, polietilenglicol, trietilenglicol, lanolina, aceite de ricino, alcoholes de lanolina acetilados, petroleum, aceite mineral, miristato de butilo, ácido isoesteárico, ácido palmítico, linoleato de isopropilo, oleato de decilo o miristato de miristilo entre otros.Another embodiment of the present invention relates to a cosmetic or dermopharmaceutical composition of mixed micelles comprising a cosmetic or dermopharmaceutically effective amount of at least one compound selected from the group of cosmetic or dermopharmaceutical adjuvants that recover and / or maintain the barrier function of the skin formed by humectants, moisture-retaining substances, moisturizers, emollients, emulsifying agents and mixtures thereof, such as and without limitation, glycerin, pentylene glycol, propylene glycol, Glycereth-26, Sorbeth-30, panthenol, trehalose and its derivatives, hyaluronic acid and its derivatives, pyroglutamic acid and its derivatives, serine, proline, glutamate, arginine, urea, creatine, glucosamines, lactic acid, lauryl lactate, myristyl lactate, polyglyceryl acrylate, ectoin and its derivatives, chitosan, N - ( 2-hydroxyethyl) acetamide, saccharide isomerate, sorbitol, pentaerythritol, inositol, xylitol, 2-pyrrolidone-5- sodium carboxylate, N- lauroyl-pyrrolidonecarboxylic acid, N- lauroyl-L-lysine, N- alpha-benzoyl-L-arginine, soluble collagen, dibutylphthalate, gelatin, stearic alcohol, glyceryl monoricinoleate, glyceryl monostearate, propan-1,2 -diol, butan-1,3-diol, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleic alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan- 2-ol, isocetyl alcohol, cetyl palmitate, dimethylpolysiloxane, di- n- butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, castor oil, alcoolin acetylated, petroleum, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, decyl oleate or myristyl myristate among others.
Adicionalmente, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad cicatrizante y/o reepitelizante o con eficacia como coadyuvantes en procesos de cicatrización y/o reepitelización como por ejemplo y sin sentido limitativo los extractos de Centella asiatica, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hyperícum perforatum, Mimosa tenuiflora, Aloe vera, Polyplant® Epithelizing [INCI: Caléndula Officinalis, Hypericum Perforatum, Chamomilla Recutita, Rosmarinus Officinalis] comercializado por Provital, Cytokinol® LS 9028 [INCI: Hydrolyzed Casein, Hydrolyzed Yeast Protein, Lysine HCI] comercializado por Laboratories Serobiologiques/Cognis o Deliner® [INCI: Zea May (Corn) Kernel Extract] comercializado por Coletica/Engelhard entre otros, y/o además una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad cicatrizante y/o reepitelizante o con eficacia como coadyuvante en procesos de cicatrización y/o reepitelización como por ejemplo y sin sentido limitativo cadherinas, integrinas, selectinas, receptores de ácido hialurónico, inmunoglobulinas, factor de crecimiento de fibroblastos, factor de crecimiento del tejido conectivo, factor de crecimiento derivado de plaquetas, factor de crecimiento endotelial vascular, factor de crecimiento epidérmico, factor de crecimiento insuliniforme, factores de crecimiento de queratinocitos, factores estimuladores de colonias, factores transformadores de crecimiento beta, factor de necrosis tumoral alfa, interferones, interleucinas, metaloproteinasas de la matriz, receptores de fosfatasas de tirosina proteínicas, Antarcticine® [INCI: Pseudoalteromonas Ferment Extract] o Decorinyl® [INCI: Tripeptide-10 Citrulline], comercializados por Lipotec, entre otros.Additionally, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with healing and / or re-epithelial activity or effectively as adjuvants in healing and / or re-epithelialization processes, for example and without limitation, the extracts of Centella asiatica, Rosa moschata, Echinacea angustifolia, Symphytum officinale, Equisetum arvense, Hyperícum perforatum, Mimosa tenuiflora, Aloe vera , Polyplant® Epithelizing [INCI: Officinal : , Hypericum Perforatum, Chamomilla Recutita, Rosmarinus Officinalis ] marketed by Provital, Cytokinol® LS 9028 [INCI: Hydrolyzed Casein, Hydrolyzed Yeast Protein, Lysine HCI] marketed by Laboratories Serobiologiques / Cognis or Deliner® [INCI: Zea May (Corn) Kernel Extract ] marketed by Colet ica / Engelhard among others, and / or in addition a cosmetic or dermopharmaceutically effective amount of at least one synthetic compound, extract or product from a biofermentation procedure with healing and / or re-epithelial activity or effectively as an adjuvant in healing processes and / or re-epithelization such as, for example and without limitation, cadherins, integrins, selectins, hyaluronic acid receptors, immunoglobulins, fibroblast growth factor, connective tissue growth factor, platelet-derived growth factor, vascular endothelial growth factor, epidermal growth, insuliniform growth factor, keratinocyte growth factors, colony stimulating factors, beta growth transforming factors, alpha tumor necrosis factor, interferons, interleukins, matrix metalloproteinases, protein tyrosine phosphatases receptors, Antarcticine® [ INCI: Pseudoalteromonas Ferment Extract] or Decorinyl® [INCI: Tripeptide-10 Citrulline], marketed by Lipotec, among others.
Adicionalmente, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad estimuladora de la síntesis de macromoléculas dérmicas o epidérmicas y/o capaces de inhibir o prevenir su degradación, como por ejemplo agentes estimuladores de la síntesis de colágeno, agentes estimuladores de la síntesis de elastina, agentes estimuladores de la síntesis de decorina, agentes estimuladores de la síntesis de laminina, agentes estimuladores de la síntesis de defensinas, agentes estimuladores de la síntesis de chaperonas, agentes estimuladores de la síntesis de ácido hialurónico, agentes estimuladores de la síntesis de aquaporinas, agentes estimuladores de la síntesis de fibronectina, agentes inhibidores de metaloproteasas de matriz, agentes inhibidores de la degradación de colágeno, agentes inhibidores de la degradación de elastina, agentes inhibidores de proteasas de serina como leucocito elastasa o catepsina G, agentes estimuladores de la proliferación de fibroblastos, agentes estimuladores de la proliferación de queratinocitos, agentes estimuladores de la diferenciación de queratinocitos, agentes estimuladores de la proliferación de adipocitos, agentes estimuladores de la diferenciación de adipocitos, agentes estimuladores de la angiogénesis, agentes estimuladores de la síntesis de glicosaminoglicanos, agentes reparadores del ADN y/o agentes protectores del ADN, como por ejemplo y sin sentido limitativo extractos de Centella asiatica, Saccharomyces cerivisiae, Solanum tuberosum, Rosmarinus officinalis, Vaccinium angustifolium, extracto de las algas Macrocystis pyrifera, Padina pavonica, extracto de las plantas de soja, malta, lino, salvia, trébol rojo, kakkon, altramuz, extracto de avellana, de maíz, extracto de levadura, extracto de brotes de haya, extracto de semillas de leguminosas, extracto de hormonas vegetales tales como giberelinas, auxinas o citoquininas entre otras, o extracto de zooplancton Salina entre otros y/o además una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad estimuladora de la síntesis de macromoléculas dérmicas o epidérmicas y/o capaces de inhibir o prevenir su degradación como por ejemplo y sin sentido limitativo el producto de fermentación de la leche con Lactobacillus Bulgaricus, asiaticósidos y sus derivados, vitamina C y sus derivados, ácido cinámico y sus derivados, Matrixyl® [INCI: Palmitoyl Pentapeptide-3], Matrixyl® 3000 [INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] o Biopeptide CL^{TM} [INCI: Glyceryl Polymethacrylate, Propylene Glycol, Palmitoyl Oligopeptide] comercializados por Sederma, Antarcticine [INCI:_ Pseudomonas ferment extract] comercializado por Lipotec, Drieline® PF [INCI:Yeast Betaglucan] comercializado por Alban Muller, Phytovityl C® [INCI: Aqua, Zea Mays Extract] comercializado por Solabia, Collalift® [INCI: Hydrolyzed Malt Extract] comercializado por Coletica/Engelhard, Phytocohesine® PSP [proposed INCI: Sodium Beta-Sitosterol Sulfate] comercializado por Seporga, minerales como calcio entre otros, retinoides y sus derivados, isoflavonoides, carotenoides, en particular licopeno, pseudodipéptidos, retinoides y sus derivados como retinol o palmitato de retinilo entre otros, o heparinoides entre otros.Additionally, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from the cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with stimulating activity of the synthesis of dermal or epidermal macromolecules and / or capable of inhibiting or preventing its degradation, such as collagen synthesis stimulating agents, elastin synthesis stimulating agents, decorin synthesis stimulating agents, laminin synthesis stimulating agents, synthesis stimulating agents of defensins, chaperone synthesis stimulating agents, hyaluronic acid synthesis stimulating agents, aquaporin synthesis stimulating agents, fibronectin synthesis stimulating agents, matrix metalloprotease inhibiting agents, d inhibiting agents and collagen degradation, elastin degradation inhibitors, serine protease inhibitors such as leukocyte elastase or cathepsin G, fibroblast proliferation stimulating agents, keratinocyte proliferation stimulating agents, keratinocyte differentiation stimulating agents , adipocyte proliferation stimulating agents, adipocyte differentiation stimulating agents, angiogenesis stimulating agents, glycosaminoglycan synthesis stimulating agents, DNA repairing agents and / or DNA protective agents, such as without limitation extracts of Centella asiatica, Saccharomyces cerivisiae, Solanum tuberosum, Rosmarinus officinalis, Vaccinium angustifolium , algae extract Macrocystis pyrifera, Padina pavonica , soybean plant extract, malt, flax, sage, red clover, kakkon, lupine extract, lupine , corn, levad extract ura, beech sprout extract, legume seed extract, plant hormone extract such as gibberellins, auxins or cytokinins among others, or saline zooplankton extract among others and / or also a cosmetic or dermopharmaceutically effective amount of at least one compound synthetic, extract or product from a biofermentation procedure with activity that stimulates the synthesis of dermal or epidermal macromolecules and / or capable of inhibiting or preventing its degradation, for example and without limitation, the milk fermentation product with Lactobacillus Bulgaricus , Asiaticosides and their derivatives, vitamin C and its derivatives, cinnamic acid and its derivatives, Matrixyl® [INCI: Palmitoyl Pentapeptide-3], Matrixyl® 3000 [INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] or Biopeptide CL ™ [ INCI: Glyceryl Polymethacrylate, Propylene Glycol, Palmitoyl Oligopeptide] marketed by Sederma, Antarcticine [INCI: _ Pseudo monas ferment extract] marketed by Lipotec, Drieline® PF [INCI: Yeast Betaglucan] marketed by Alban Muller, Phytovityl C® [INCI: Aqua, Zea Mays Extract] marketed by Solabia, Collalift® [INCI: Hydrolyzed Malt Extract] marketed by Coletica / Engelhard, Phytocohesine® PSP [proposed INCI: Sodium Beta-Sitosterol Sulfate] marketed by Seporga, minerals such as calcium among others, retinoids and their derivatives, isoflavonoids, carotenoids, in particular lycopene, pseudopeptides, retinoids and their derivatives such as retinol or palmitate retinyl among others, or heparinoids among others.
Adicionalmente, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad reafirmante, redensificante y/o reestructurante como por ejemplo y sin sentido limitativo los extractos de Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Aloe Barbadensis, Panicum miliaceum, Morus nigra, Sesamum indicum, Glycine soja, Tríticum vulgare, Pronalen® Refirming HSC [INCI: Triticum vulgare, Silybum Marianum, Glycine Soy, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus] o Polyplant® Refirming [INCI: Coneflower, Asiatic Centella, Fucus, Fénugreek] comercializados por Provital, Lanablue® [INCI: Sorbitol, Algae Extract] comercializado por Atrium Innovations, Pepha®-Nutrix [INCI: Natural Nutrition Factor] comercializado por Pentapharm, o extractos vegetales que contengan isoflavonas y/o al menos un compuesto sintético, extracto o producto de biofermentación con actividad reafirmante, redensificante y/o reestructurante como por ejemplo y sin sentido limitativo Biopeptide EL^{TM} [INCI: Palmitoyl Oligopeptide], Biopeptide CL^{TM} [INCI: Palmitoyl Oligopeptide], Vexel® [INCI: Water (Aqua), Propylene Glycol, Lecithin, Caffeine, Palmitoyl Carnitine], Matrixyl® [INCI: Palmitoyl Pentapeptide-3], Matrixyl® 3000 [INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] o Bio-Bustyl^{TM} [INCI: Glyceryl Polymethacrylate, Rahnella Soy Protein Ferment, Water (Aqua), Propylene Glycol, Glycerin, PEG-8, Palmitoyl Oligopeptide] comercializados por Sederma, Dermosaccharides® HC [INCI: Glycerin, Water (Aqua), Glycosaminoglycans, Glycogen], Aglycal® [INCI: Mannitol, Cyclodextrin, Glycogen, Aratostaphylos Uva Ursi Leaf Extract], Cytokinol® LS [INCI: Hydrolyzed Casein, Hydrolyzed Yeast Protein, Lysine HCL] o Firmiderm® LS9120 [INCI: Terminalia Catappa Leaf extract, Sambucus Negra Flower Extract, PVP, Tannic Acíd] comercializados por Laboratoires Serobiologiques/Cognis, Liftline® [INCI: Hydrolyzed wheat protein], Raffermine® [INCI: Hydrolyzed Soy Flour] o Ridulisse C® [Hydrolyzed Soy Protein] comercializados por Silab, Serilesine® [INCI: hexapeptide-10] o Decorinyl^{TM} [INCI: Tripeptide-10 Citrulline] comercializados por Lipotec, Ursolisome® [INCI: Lecithin, Ursolic Acid, Atelocollagen, Xanthan Gum, Sodium Chondroitin Sulfate] o Collalift® [INCI: Hydrolyzed Malt Extract] comercializados por Coletica/Engelhard, Syn®-Coll [INCI: Palmitoyl Tripeptide-5] comercializado por Pentapharm, Hydriame® [INCI: Water (Aqua), Glycosaminoglycans, Sclerotium Gum] comercializado por Atrium Innovations o IP2000 [INCI: Dextran, Trifluoroacetyl tripeptide-2] comercializado por Instituí Europeen de Biologie Cellulaire entre otros.Additionally, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from the cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with firming, redensifying and / or restructuring activity such as for example without limiting sense , Malpighia punicitolia, Cynara scolymus, Gossypium herbaceum, Aloe Barbadensis, Panicum miliaceum, Morus nigra, Sesamum indicum, Glycine soja, Triticum vulgare, Pronalen® Refirming HSC [INCI: Triticum vulgare, Silybum Marianum, Glycine soy, Equisetum Arvense, Alchemilla Vulgaris, Medicago Sativa, Raphanus Sativus ] or Polyplant® Refirming [INCI: Coneflower, Asiatic Centella, Fucus, Fénugreek] marketed by Provital, Lanablue® [INCI: Sorbitol, Algae Extract] marketed by Atrium Innovations, Pepha® Nutrix [INCI: Natural Nutrition Factor] marketed by Pentaphar m, or plant extracts containing isoflavones and / or at least one synthetic compound, extract or biofermentation product with firming, redensifying and / or restructuring activity as for example and without limiting sense Biopeptide EL ™ [INCI: Palmitoyl Oligopeptide] , Biopeptide CL ™ [INCI: Palmitoyl Oligopeptide], Vexel® [INCI: Water (Aqua), Propylene Glycol, Lecithin, Caffeine, Palmitoyl Carnitine], Matrixyl® [INCI: Palmitoyl Pentapeptide-3], Matrixyl® 3000 [ INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] or Bio-Bustyl ™ [INCI: Glyceryl Polymethacrylate, Rahnella Soy Protein Ferment, Water (Aqua), Propylene Glycol, Glycerin, PEG-8, Palmitoyl Oligopeptide] marketed by Sederma, Dermosaccharides® HC [INCI: Glycerin, Water (Aqua), Glycosaminoglycans, Glycogen], Aglycal® [INCI: Mannitol, Cyclodextrin, Glycogen, Aratostaphylos Uva Ursi Leaf Extract], Cytokinol® LS [INCI: Hydrolyzed Casein, Hydrolyzed Yeast HCL] or Firmiderm® LS9120 [INCI: Terminalia Catappa Leaf extract, Sambucus Negra Flower Extract, PVP, Tannic Acid] marketed by Laboratoires Serobiologiques / Cognis, Liftline® [INCI: Hydrolyzed wheat protein], Raffermine® [INCI: Hydrolyzed Soy Flour] or Ridulisse C® [Hydrolyzed I am Protein] marketed by Silab, Serilesine® [INCI: hexapeptide-10] or Decorinyl ™ [INCI: Tripeptide-10 Citrulline] marketed by Lipotec, Ursolisome® [INCI: Lecithin, Ursolic Acid, Atelocollagen, Xanthan Gum, Sodium Chondroitin Sulfate] or Collalift® [INCI: Hydrolyzed Malt Extract] marketed by Coletica / Engelhard, Syn®-Coll [INCI: Palmitoyl Tripeptide-5] marketed by Pentapharm, Hydriame® [INCI: Water (Aqua), Glycosaminoglycans, Sclerotium Gum] marketed by Atrium Innovations or IP2000 [INCI: Dextran, Trifluoroacetyl tripeptide-2] marketed by Instití Europeen de Biologie Cellulaire among others.
Además, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad anti-glicación como por ejemplo y sin sentido limitativo los extractos de Vaccinium angustifolium entre otros, y/o además una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad anti-glicación como por ejemplo y sin sentido limitativo ergotioneína y sus derivados, lisina, Aldenine® [INCI: Hydrolized Wheat Protein, Hydrolized Soy Protein, Tripeptide-1] o Eyeseryl® [INCI: Acetyl Tetrapeptide-5] comercializados por Lipotec, hidroxiestilbenos y sus derivados, resveratrol o 3,3',5,5'-tetrahidroxiestilbeno entre otros.In addition, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with anti-glycation activity as for example and without limiting sense. Extracts of Vaccinium angustifolium among others, and / or also a cosmetic or dermopharmaceutically effective amount of at least one synthetic compound, extract or product from a biofermentation procedure with anti-glycation activity such as, for example, and without limiting sense ergotioneína and its derivatives , lysine, Aldenine® [INCI: Hydrolized Wheat Protein, Hydrolized Soy Protein, Tripeptide-1] or Eyeseryl® [INCI: Acetyl Tetrapeptide-5] marketed by Lipotec, hydroxystilbenes and their derivatives, resveratrol or 3.3 ', 5.5 '-tetrahydroxiestilbeno among others.
La composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad inhibidora de la NO-sintasa como por ejemplo y sin sentido limitativo los extractos de plantas Vitis vinifera, Olea europaea o Gingko biloba entre otros.The cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise, among cosmetic or dermopharmaceutical adjuvants, a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with NO-synthase inhibitory activity, for example and nonsense Limiting plant extracts Vitis vinifera, Olea europaea or Gingko biloba among others.
Asimismo, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad capturadora de radicales libres y/o anti-contaminación atmosférica como por ejemplo y sin sentido limitativo extracto de té, extracto de hoja de olivo, extracto de Rosmarinus officinalis o extracto de Eichhornia crassipes y/o al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad capturadora de radicales libres y/o anti-contaminación atmosférica como por ejemplo y sin sentido limitativo benzopirenos, metales pesados tales como cobalto, mercurio, cadmio o níquel, vitamina C y sus derivados, vitamina E y sus derivados, en particular acetato de tocoferol, glicósido de ascorbilo, fenoles y polifenoles, en particular taninos, ácido tánico y ácido elágico, galocatecol, antocianos, ácido clorogénico, estilbenos, índoles, derivados de aminoácidos que contienen cisteína, en particular N-acetilcisteína, ergotioneína, S-carboximetilcisteína, agentes quelantes, en particular EDTA o etilendiaminas, caroténoides, bioflavonoides, ubiquínona, idebenona, catalasa, superóxido de dismutasa, lactoperoxidasa, glutatión de peroxidasa, glutatión, benzilidenalcanfor, pidolatos, lignanos, melatonina, orizanol, Aldenine® [INCI: Hydrolized wheat protein, hydrolized soy protein, tripeptide-1] o Lipochroman-6 [INCI: Dimethylmethoxy Chromanol] comercializados por Lipotec entre otros.Also, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with free radical capture and / or anti-contamination activity. atmospheric, for example and without limitation, tea extract, olive leaf extract, Rosmarinus officinalis extract or Eichhornia crassipes extract and / or at least one synthetic compound, extract or product from a biofermentation procedure with radical capture activity free and / or anti-air pollution such as, for example and without limitation, benzopyrenes, heavy metals such as cobalt, mercury, cadmium or nickel, vitamin C and its derivatives, vitamin E and its derivatives, in particular tocopherol acetate, ascorbyl glycoside , phenols and polyphenols, in particular tannins, tannic acid and ellagic acid, gallocatecol, anthocyanins, chlorogenic acid, stilbenes, idols, amino acid derivatives containing cysteine, in particular N- acetylcysteine, ergotionein, S-carboxymethylcysteine, chelating agents, in particular EDTA or ethylenediamines, carotenoids, bioflavonoids, ubiquinonaids , idebenone, catalase, dismutase superoxide, lactoperoxidase, peroxidase glutathione, glutathione, benzylidenal camphor, pidolates, lignans, melatonin, oryzanol, Aldenine® [INCI: Hydrolized wheat protein, hydrolized soy protein, tripeptide-1] or Lipochroman-6 [INCI : Dimethylmethoxy Chromanol] marketed by Lipotec among others.
Adicionalmente, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad inhibidora de la 5\alpha-reductasa como por ejemplo y sin sentido limitativo extracto de Cinnamommum zeylanicum, Laminaria saccharina, Spiraea ulmaria, Serenoa repens, extractos de plantas Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salvia officinalis, Thymus vulgaricus, extracto de plantas del género Silybum, extracto de plantas que contienen sapogeninas y en particular extracto de plantas de Dioscorea entre otros y/o además una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad inhibidora de la 5\alpha-reductasa como por ejemplo y sin sentido limitativo retinoides y en particular retinol, azufre y sus derivados, sales de zinc y en particular lactato, gluconato, pidolato, carboxilato, salicilato o cisteato de zinc, cloruro de selenio, vitamina B6, piridoxina, capriloil glicina o sarcosina entre otros.Additionally, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from the cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with 5α-reductase inhibitory activity as per example and without limiting sense Cinnamommum zeylanicum extract , Laminaria saccharina, Spiraea ulmaria, Serenoa repens , plant extracts Arnica montana, Cinchona succirubra, Eugenia caryophyllata, Humulus lupulus, Hypericum perforatum, Mentha piperita, Rosmarinus officinalis, Salviaymusinalinalis, Salviaus officinalis, Salvia officinalicus, Salvia thymus officinalis, Salvia thymus officinalis, Salvia officinalis, Thirsty of plants of the genus Silybum, extract of plants containing sapogenins and in particular extract of Dioscorea plants among others and / or also a cosmetic or dermopharmaceutically effective amount of at least one synthetic compound, extract or product from a biofermentation process n with 5α-reductase inhibitory activity such as for example and without limitation retinoids and in particular retinol, sulfur and its derivatives, zinc salts and in particular lactate, gluconate, pidolate, carboxylate, salicylate or zinc cysteate, chloride of selenium, vitamin B6, pyridoxine, capriloyl glycine or sarcosine among others.
Asimismo, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético con actividad inhibidora de lisil- y/o prolil-hidroxilasa como por ejemplo y sin sentido limitativo 2,4-diaminopirimidina 3-óxido o 2,4-diamino-6-piperidinopirimidina 3-óxido entre otros.Also, the cosmetic composition or Mixed micellar dermopharmaceutical of the present invention can understand between cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least a synthetic compound with lysyl- and / or inhibitory activity prolyl hydroxylase as for example and meaningless limiting 2,4-diaminopyrimidine 3-oxide or 2,4-diamino-6-piperidinopyrimidine 3-oxide among others.
La composición cosmética o dermofarmacéutica de la invención también puede contener adicionalmente de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un agente bactericida y/o bacteriostático y/o un agente fungicida y/o un agente fungistático, como por ejemplo y sin sentido limitativo caprililglicol, imidazolinidil urea, 4-hidroxibenzoato de metilo [INCI: methylparaben], 4-hidroxibenzoato de etilo [INCI: ethylparaben], 4-hidroxibenzoato de propilo [INCI: propylparaben], 4-hidroxibenzoato de butilo [INCI: butylparaben], 4-hidroxibenzoato de isobutiio [INCI: isobutylparaben], 1,3-bis(hidroximetil)-5,5-dimetilimidazolidino-2,4-diona [INCI: DMDM Hydantoin], 4-hidroxibenzoato de bencilo [INCI: benzylparaben], alcohol benzílico, ácido deshidroacético, ácido benzoico, ácido sórbico, ácido salicílico, ácido fórmico, ácido propiónico, 2-bromo-2-nitropropan-1,3-diol, 3-p-clorofenoxi-1,2-propanodiol [INCI: chlorphenesin], alcohol diclorobenzílico, butilcarbamato de yodopropinilo/cloruro de benzalconio, cloruro de bencetonio, clorhexidina, etanol, isopropanol, metanol, 1,2-hexanodiol, 1,2-octanodiol, pentilenglicol, laurato de glicerina, caprilato de glicerina, caprato de glicerina, peróxido de benzoilo, gluconato de clorhexidina, triclosan, fenoxietanol, terpinen-4-ol, \alpha-terpineol, resorcinol, estimicina, eritromicina, neomicina, clindamicina y sus esteres, tetraciclinas, metronidazol, ácido azelaico, tolnaftato, nistatina, clortrimazol, ketoconazol, piritionato de zinc, óxido de zinc, isotiazolinonas, sulfuro de selenio, benzilhemiformal, ácido bórico, borato de sodio, 6,6-dibromo-4,4-dicloro-2,2'-metilendifenol [INCI: bromochlorophene], 5-bromo-5-nitro-1,3-dioxano, tosilcioramida sódica [INCI: chloramine T], cloroacetamida, p-cloro-m-cresol, 2-benzil-4-clorofenol [INCI: chlorophene], dimetil oxazolidina, bromuro de dodecildimetil-2-fenoxietil amonio [INCI: domiphen bromide], 7-etilbiciclooxazolidina, hexetidina, glutaraldehido, N-(4-clorofenil)-N-[4-cloro-3-(trifluorometil)fenil]-urea [INCI: cloflucarban], 2-hidroxi-4-isopropil-2,4,6-cicloheptatrien-1-ona [INCI: Hinokitiol], isopropilmetilfenol, sales de mercurio, sales de aluminio, nisina, fenoxiisopropanol, o-fenilfenol, yoduro de 3-heptil-2-[(3-heptil-4-metil-3H-tiazol-2-iliden)metil]-4-metiltiazolio [INCI: Quaternium-73], cloruro de plata, yodato de sodio, timol, ácido undecilenico, ácido dietilentriaminpentaacético, ácido etilendiamintetraacético, lactoperoxidasa, glucosa oxidasa, lactoferrina, y/o una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto natural o aceite esencial con actividad bactericida, bacteriostática, fungicida y/o fungistática intrínseca como por ejemplo y sin sentido limitativo los extractos de Allium sativum, Caléndula officinalis, Chamomilla recutita, Echinacea Purpura, Hyssopus Officinalis, Melaleuca alternifolia o el aceite del árbol del té entre otros.The cosmetic or dermopharmaceutical composition of the invention may also additionally contain from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one bactericidal and / or bacteriostatic agent and / or a fungicidal agent and / or a fungistatic agent, as per example and without limitation caprililglicol, imidazolinidyl urea, methyl 4-hydroxybenzoate [INCI: methylparaben], ethyl 4-hydroxybenzoate [INCI: ethylparaben], propyl 4-hydroxybenzoate [INCI: propylparaben], 4-hydroxybenzoate [ : butylparaben], isobutyium 4-hydroxybenzoate [INCI: isobutylparaben], 1,3-bis (hydroxymethyl) -5,5-dimethylimidazolidino-2,4-dione [INCI: DMDM Hydantoin], benzyl 4-hydroxybenzoate [INCI: benzylparaben], benzyl alcohol, dehydroacetic acid, benzoic acid, sorbic acid, salicylic acid, formic acid, propionic acid, 2-bromo-2-nitropropan-1,3-diol, 3- p- chlorophenoxy-1,2-propanediol [ INCI: chlorphenesin], dichlorobenzyl alcohol, iodopropyl butylcarbamate / benzalkonium chloride, benzethonium chloride, chlorhexidine, ethanol, isopropanol, methanol, 1,2-hexanediol, 1,2-octanediol, pentylene glycol, glycerin laurate, caprilato, carylate Glycerin caprate, benzoyl peroxide, chlorhexidine gluconate, triclosan, phenoxyethanol, terpinen-4-ol, α-terpineol, resorcinol, stimicin, erythromycin, neomycin, clindamycin and its esters, tetracyclines, metronidazole, azelatinic acid, tolhetic acid, tolleic acid , chlortrimazole, ketoconazole, zinc pyrithione, zinc oxide, isothiazolinones, selenium sulfide, benzylhemiformal, boric acid, sodium borate, 6,6-dibromo-4,4-dichloro-2,2'-methylenediphenol [INCI: bromochlorophene ], 5-Bromo-5-nitro-1,3-dioxane, sodium tosylcioramide [INCI: chloramine T], chloroacetamide, p- chloro- m -cresol, 2-benzyl-4-chlorophenol [INCI: chlorophene], dimethyl oxazolidine , dodecyldimethyl-2-phenoxyethyl ammonium bromide [INCI: domiphen bromide], 7-ethylbicyclooxazolidine, hexetidine, glutaraldehyde, N - (4-chlorophenyl) - N - [4-chloro-3- (trifluoromethyl) phenyl] -urea [INCI: cloflucarban], 2-hydroxy-4-isopropyl-2 , 4,6-cycloheptatrien-1-one [INCI: Hinokitiol], isopropylmethylphenol, mercury salts, aluminum salts, nisin, phenoxyisopropanol, o-phenylphenol, 3-heptyl-2 - [(3-heptyl-4- iodide] methyl-3 H -thiazol-2-ylidene) methyl] -4-methylthiazolium [INCI: Quaternium-73], silver chloride, sodium iodate, thymol, undecylenic acid, diethylenetriaminepentaacetic acid, ethylenediaminetetraacetic acid, lactoperoxidase, glucose oxidase, lactoferrin , and / or a cosmetic or dermopharmaceutically effective amount of at least one natural extract or essential oil with bactericidal, bacteriostatic, fungicidal and / or intrinsic fungistatic activity such as for example and without limitation the extracts of Allium sativum, Calendula officinalis, Chamomilla recutita, Purple Echinacea, Hyssopus Officinalis, Melaleuca alternifolia or oil d The tea tree among others.
Asimismo, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético o combinación de compuestos sintéticos con actividad descamante como por ejemplo y sin sentido limitativo alfahidroxiácidos, y en particular ácido glicólico, ácido láctico, ácido cítrico, ácido tartárico, ácido málico y/o ácido mandélico entre otros, betahidroxiácidos, como por ejemplo y sin sentido limitativo ácido salicílico y sus derivados, así como el empleo de urea y sus derivados, hidroxiestilbenos, resveratrol, N-acetilglucosamina, ácido jasmónico y sus derivados, ácido cinámico, ácido gentísico, oligofucosas, detergentes y/o enzimas, como por ejemplo y sin sentido limitativo, sutilaínas, papaína o bromelaína o bien al menos un extracto o combinación de extractos de Saphora japónica, papaya, piña, calabaza o batata entre otros.Also, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one synthetic compound or combination of synthetic compounds with descaling activity such as for example and without limiting sense. alphahydroxy acids, and in particular glycolic acid, lactic acid, citric acid, tartaric acid, malic acid and / or mandelic acid, among others, betahydroxy acids, for example and without limitation salicylic acid and its derivatives, as well as the use of urea and its derivatives, hydroxystilbenes, resveratrol, N- acetylglucosamine, jasmonic acid and its derivatives, cinnamic acid, gentisic acid, oligofucoses, detergents and / or enzymes, for example and without limitation, subtylains, papain or bromelain or at least one extract or combination of extracts of saphora japan , papaya, pineapple, squash or sweet potato among others.
Asimismo, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto analgésico y/o compuesto antiinflamatorio. Entre dichos compuestos pueden destacarse compuestos sintéticos como la hidrocortisona, clobetasol, dexametasona, prednisona, paracetamol, ácido acetilsalicílico, amoxiprin, benorilato, salicilato de colina, diflunisal, faislamina, salicilato de metilo, salicilato de magnesio, salsalato, diclofenaco, aceclofenaco, acemetacina, bromfenaco, etodolac, indometacina, sulindaco, tolmetin, ibuprofeno, carprofeno, fenbufeno, fenoprofeno, flurbiprofeno, ketoprofeno, ketorolac, loxoprofeno, naproxeno, oxaprozina, ácido tiaprofenico, suprofeno, ácido mefenamico, meclofenamato, ácido meclofenamico, nabumetona, fenilbutazona, azapropazona, metamizol, oxifenbutazona, sulfinpirazona, piroxicam, lornoxicam, meloxicam, tenoxicam, celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib, nimesulida, licofelona, ácidos grasos omega-3 y sus biometabolitos, morfina, codeína, oxicodona, hidrocodona, diamorfina, petidina, tramadol, brupenorfina, benzocaína, lidocaína, cloroprocaína, tetracaína, procaína, antidepresivos tricíclicos, amitriptilina, carbamazepina, gabapentina, pregabalina, bisabolol, pantenol, biotina, fosfato lauriminodipropionato de tocoferilo y disodio, ciclopirox olamine, ácido nordihidroguaiarético, coenzima Q10 o éteres de alquilglicerina, o los extractos naturales o aceites esenciales con actividad analgésica y/o antiinflamatoria intrínseca, como por ejemplo y sin sentido limitativo madecassosido, equinacina, aceite de semilla de amaranto, aceite de madera de sándalo, extracto de placenta, extracto de hoja de melocotonero, Aloe vera, Arnica montana, Artemisia vulgaris, Asarum máximum, Caléndula officinalis, Capsicum, Centipeda cunninghamii, Chamomilla recutita, Crinum asiaticum, Hamamelis virginiana, Harpagophytum procumbens, Hypericum perforatum, Lilium candidum, Malva sylvestris, Mélaleuca alternifolia, Origanum mejorana, Salix alba, Silybum marianum, Tanacetum parthenium o Uncaria guianensis entre otros.Also, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from the cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one analgesic and / or anti-inflammatory compound. These compounds include synthetic compounds such as hydrocortisone, clobetasol, dexamethasone, prednisone, paracetamol, acetylsalicylic acid, amoxiprin, benorylate, choline salicylate, diflunisal, phalamine, methyl salicylate, magnesium salicylate, acetometactaenac, acetyltaccinate, diclofenac bromfenac, etodolac, indomethacin, sulindac, tolmetin, ibuprofen, carprofen, fenbufen, fenoprofen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic acid, suprofen, mefenamic acid, meclofenamate, meclofenamic acid, nabumetone, phenylbutazone, azapropazone, metamizole , oxyfenbutazone, sulfinpyrazone, piroxicam, lornoxicam, meloxicam, tenoxicam, celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib, nimesulide, licofelone, omega-3 fatty acids and their biometaboline, morphine, codex, morphine tramadol, brupenorphine, benzocaine, lidocaine, chloroprocaine, tea tracaine, procaine, tricyclic antidepressants, amitriptyline, carbamazepine, gabapentin, pregabalin, bisabolol, panthenol, biotin, lauriminodipropionate phosphate and disodium, cyclopyrox olamine, nordihydroguaaric acid or coenzyme essential oils, or extractants of q, or oils, or alterants of natural oils, or extractants of natural oils, or extractants of natural oils or aliphytes, or essential oils, or alkyls, or essential oils, or alkyls, or natural oils, or alkynes, or natural oils, or aliphytes, or essential oils, or alkynes, or essential oils, or enzymes of alkyls or aliphytes, or natural alkyls, or aliphytes, or aliphytes, as well as natural oils, or extractants, or alkyls, or essential oils, or alkynes, as well as natural oils, or extractants, or natural alkyls, or aliphytes, or natural alkynes, or acetyl, alkyls, or aliphytes, or other alkynes, as well as natural oils analgesic and / or intrinsic anti-inflammatory, such as for example and without limitation madecassosido, equinacin, amaranth seed oil, sandalwood oil, placenta extract, peach leaf extract, Aloe vera, Arnica montana, Artemisia vulgaris, Asarum maximum, Calendula officinalis, Capsicum, Centipeda cunninghamii, Chamomilla recutita, Crinum asiaticum, Hamamelis virginiana, Harpagophytum procumbens, Hypericum perforatum, Lilium candidum, Malva sylvestris, Melaleuca alternifolia, Origanum marjoram, Salix alba, Silybum marianum, Tanacetum parthenium or Uncaria guianensis , among others .
Además, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad antiarrugas y/o antienvejecimiento como por ejemplo y sin sentido limitativo los extractos de Vitis vinifera, Rosa canina, Curcuma tonga, Iris pallida, Theobroma cacao, Ginkgo biloba, o Dunaliella salina entre otros y/o al menos un compuesto sintético, extracto o producto de biofermentación con actividad antiarrugas y/o antienvejecimiento como por ejemplo y sin sentido limitativo Matrixyl® [INCI: Palmitoyl Pentapeptide-3] o Matrixyl 3000® [INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] comercializados por Sederma, Vialox® [INCI: Pentapeptide-3] o Syn-ake® [INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate] comercializados por Pentapharm, Myoxinol^{TM} [INCI: Hydrolyzed Hibiscus Esculentus Extract] comercializado por Laboratoires Sérobiologiques/Cognis, Algisum C® [INCI: Methylsilanol Mannuronate] o Hydroxyprolisilane CN® [INCI: Methylsilanol Hydroxyproline Aspartate] comercializados por Exsymol, Argireline® [INCI: Acetyl Hexapeptide-8], Leuphasyl® [INCI: Pentapeptide-18], Aldenine® [INCI: Hydrolized wheat protein, hydrolized soy protein, tripeptide-1], Eyeseryl® [INCI: Acetyl Tetrapeptide-5], Trylagen^{TM} [INCI: Pseudoalteromonas Ferment Extract, Hydrolyzed Wheat Protein, Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1] o Lipochroman-6 [INCI: Dimethylmethoxy Chromanol] comercializados por Lipotec, Kollaren® [INCI: Tripeptide-1, Dextran] comercializado por Instituí Europeen de Biologie Cellulaire, Collaxyl® [INCI: Hexapeptide-9] o Quintescine® [INCI: Water, Butylene Glycol, Dipeptide-4] comercializados por Vincience, BONT-L-Peptide [proposed INCI: Palmitoyl Hexapeptide] comercializado por Infinitec Activos, antagonistas del canal de Ca^{2+} como la alverina, las sales de manganeso o de magnesio, ciertas aminas secundarias o terciarias, retinol y sus derivados, idebenona, coenzima Q10 y sus derivados, ácido boswélico y sus derivados o agonistas de canales de cloruro entre otros.In addition, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with anti-wrinkle and / or anti-aging activity as for example and without limiting sense the extracts of Vitis vinifera, Rosa canina, Curcuma tonga, Iris pallida, Theobroma cacao, Ginkgo biloba , or Dunaliella saline among others and / or at least one synthetic compound, extract or biofermentation product with anti-wrinkle and / or anti-aging activity such as for example and without limiting sense Matrixyl® [INCI: Palmitoyl Pentapeptide-3] or Matrixyl 3000® [INCI: Palmitoyl Tetrapeptide-3, Palmitoyl Oligopeptide] marketed by Sederma, Vialox® [INCI: Pentapeptide-3] or Syn-ake® [ INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate] marketed by Pentapharm, Myoxinol ™ [INCI: Hydrolyzed Hib iscus Esculentus Extract] marketed by Laboratoires Sérobiologiques / Cognis, Algisum C® [INCI: Methylsilanol Mannuronate] or Hydroxyprolisilane CN® [INCI: Methylsilanol Hydroxyproline Aspartate] marketed by Exsymol, Argireline® [INCI: Acetyl Hexapeptide-8® : Pentapeptide-18], Aldenine® [INCI: Hydrolized wheat protein, hydrolized soy protein, tripeptide-1], Eyeseryl® [INCI: Acetyl Tetrapeptide-5], Trylagen ™ [INCI: Pseudoalteromonas Ferment Extract, Hydrolyzed Wheat Protein , Hydrolyzed Soy Protein, Tripeptide-10 Citrulline, Tripeptide-1] or Lipochroman-6 [INCI: Dimethylmethoxy Chromanol] marketed by Lipotec, Kollaren® [INCI: Tripeptide-1, Dextran] marketed by Instití Europeen de Biologie Cellulaire, Collaxyl® [ INCI: Hexapeptide-9] or Quintescine® [INCI: Water, Butylene Glycol, Dipeptide-4] marketed by Vincience, BONT-L-Peptide [proposed INCI: Palmitoyl Hexapeptide] marketed by Infinitec Active, can antagonists to Ca 2+ such as alverin, manganese or magnesium salts, certain secondary or tertiary amines, retinol and its derivatives, idebenone, coenzyme Q10 and its derivatives, boswellic acid and its derivatives or chloride channel agonists among others.
Adicionalmente, la composición cosmética o dermofarmacéutica de micelas mixtas de la presente invención puede comprender de entre los adyuvantes cosméticos o dermofarmacéuticos una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un extracto o combinación de extractos con actividad despigmentante como por ejemplo y sin sentido limitativo los extractos de Achillea millefolium, Aloe vera, Aradirachta indica, Asmuna japónica, Autocarpus incisus, Bidens pilosa, Broussonetia papyrifera, Chlorella vulgaris, Cimicifuga racemosa, Emblica officinalis, Glycyrrhiza glabra, Glycyrrhiza uralensis, Ilex purpurea, Ligusticum lucidum, Ligusticum wallichii, Mitracarpus scaber, Morinda citrifolia, Morus alba, Morus bombycis, Naringi crenulata, Prunus domesticus, Pseudostellariae radix, Rumex crispus, Rumex occidentalis, Sapindus mukurossi, Saxifragia sarmentosa, Scutellaria Galericulate, Sedum sarmentosum Bunge, Stellaria medica, Triticum Vulgare, Uva ursi o Whitania somnífera entre otros, y/o además una cantidad cosmética o dermofarmacéuticamente eficaz de al menos un compuesto sintético, extracto o producto proveniente de un procedimiento de biofermentación con actividad despigmentante como por ejemplo y sin sentido limitativo Lipochroman-6 [INCI: Dimethylmethoxy Chromanol] (6-hidroxi-7-metoxi-2,2-dimetilcromano) o Chromabright^{TM} [proposed INCI: Dimethylmethoxy Chroman Palmitate] comercializados por Lipotec, Actiwhite^{TM} LS9808 [INCI: Aqua, Glycerin, Sucrose Dilaurate, Polysorbate 20, Pisum sativum (Pea) extract] o Dermawhite® NF LS9410 [INCI: Mannltol, Arginine HCI, Phenylalanine, Disodium EDTA, Sodium Citrate, Kojic Acid, Citric Acid, Yeast Extract] comercializados por Laboratoires Serobiologiques/Cognis, Lumiskin^{TM} [INCI: Caprylic/Capric Triglycerid, Diacetyl-Boldine], Melaclear^{TM} [INCI: Glycerin, Aqua, Dithiaoctanediol, Gluconic acid, Sutilains, Beta-carotene]., O.D.A.white^{TM} [INCI: octadecendioic acid] o Etioline^{TM} [INCI: Glycerin, Butylene Glycol, Arctostaphylos uva ursi Leaf Extract, Mitracarpus scaber Extract] comercializados por Sederma, Sepiwhite^{TM} MSH [INCI: Undecylenoyl Phenylalanine] comercializado por Seppic, Achromaxyl [INCI: Aqua, Brassica napus Extract] comercializado por Vincience, Gigawhite^{TM} [INCI: Aqua, Glycerin, Malva sylvestris (Mallow) Extract, Mentha piperita Leaf Extract, Primula veris Extract, Alchemilla vulgaris Extract, Verónica officinalis Extract, Melissa officinalis Leaf Extract, Achillea millefolium Extract], Melawhite® [INCI: Leukocyte Extract, AHA] o Melfade®-J [INCI: Aqua, Arctostaphylos uva-ursi Leaf Extract, Glycerin, Magnesium Ascorbyl Phosphate] comercializados por Pentapharm, Albatin® [INCI: Aminoethylphosphoric Acid, Butylene Glycol, Aqua] comercializado por Exsymol, Tyrostat^{TM}-11 [INCI: Aqua, Glycerin, Rumex occidentalis Extract] o Melanostatine®-5 [INCI: Dextran, Nonapeptide-1] comercializados por Atrium Innovations, arbutina y sus isómeros, ácido kójico y sus derivados, vitamina C y sus derivados como por ejemplo y sin sentido limitativo el ácido 6-O-palmitoilascórbico, ácido dipalmitoilascórbico, la sal magnésica del ácido ascórbico-2-fosfato (MAP), la sal sódica del ácido ascórbico-2-fosfato (NAP), ascorbilglucósido o tetraisopalmitato de ascorbilo (VCIP) entre otros, retinol y sus derivados incluyendo tretinoina e isotretinoina, idebenona, ácido hidroxibenzoico y sus derivados, flavonoides, extracto de soja, extracto de limón, extracto de naranja, extracto de ginkgo, extracto de pepino, extracto de geranio, extracto de gayuba, extracto de algarroba, extracto de canela, extracto de mejorana, extracto de romero, extracto de clavo, extracto soluble de regaliz, extracto de hojas de mora, niacinamida, liquiritina, resorcinol y sus derivados, hidroquinona, \alpha-tocoferol, \gamma-tocoferol, ácido azelaico, azeloglicina, resveratrol, sales de mercurio, ácido linoleico, ácido \alpha-lipoico, ácido dihidrolipoico, alfahidroxiácidos, betahidroxiácidos, ácido elágico, ácido ferúlico, ácido cinámico, ácido oleanólico, aloesina y sus derivados y/o inhibidores de proteasas de serina, como por ejemplo y sin sentido limitativo inhibidores de triptasa, de tripsina o de PAR-2, entre otros.Additionally, the cosmetic or dermopharmaceutical composition of mixed micelles of the present invention may comprise from among cosmetic or dermopharmaceutical adjuvants a cosmetic or dermopharmaceutically effective amount of at least one extract or combination of extracts with depigmenting activity such as for example and without limiting sense the extracts of Achillea millefolium, Aloe vera, Aradirachta indica, Asmuna japan, Autocarpus incisus, Bidens pilosa, Broussonetia papyrifera, Chlorella vulgaris, Cimicifuga racemosa, Emblica officinalis, Glycyrrhiza glabra, Glycyrrhiza liglepusum, luralepumumumumum, Ligurumumumumumumumumumum, Ligurumumumumumumumumumum, urallumumum, uralepus, uralepus, uralepraum, uralepus, urallus citrifolia, Morus alba, Morus bombycis, Naringi crenulata, Prunus domesticus, Pseudostellariae radix, Rumex crispus, Rumex occidentalis, Sapindus Mukurossi, Saxifragia sarmentosa, Scutellaria Galericulate, Sedum sarmentosum Bunge, Stellaria medica, Triticum Vulgare, Uva ursi or Withania somnifera and among others, and / or also a cosmetic or dermopharmaceutically effective amount of at least one synthetic compound, extract or product from a biofermentation process with depigmenting activity such as and without limitation Lipochroman-6 [INCI: Dimethylmethoxy Chromanol] (6 -hydroxy-7-methoxy-2,2-dimethylchroman) or Chromabright? [proposed INCI: Dimethylmethoxy Chroman Palmitate] marketed by Lipotec, Actiwhite? LS9808 [INCI: Aqua, Glycerin, Sucrose Dilaurate, Polysorbate 20, Pisum sativum (Pea) extract] or Dermawhite® NF LS9410 [INCI: Mannltol, Arginine HCI, Phenylalanine, Disodium EDTA, Sodium Citrate, Kojic Acid, Citric Acid, Yeast Extract] marketed by Laboratoires Serobiologiques / Cognis, Lumiskin ™ [ INCI: Caprylic / Capric Triglycerid, Diacetyl-Boldine], Melaclear? [INCI: Glycerin, Aqua, Dithiaoctanediol, Gluconic acid, Sutilains, Beta-carotene]., ODAwhite? [INCI: octadecendioic acid] or Etioline ? [INCI: Glycerin, Butylene Glycol, Arctostaphylos grape ursi Leaf Extract, Mitracarpus scaber Extract] marketed by Sederma, Sepiwhite? MSH [INCI: Undecylenoyl Phenylalanine] marketed by Seppic, Achromaxyl [INCI: Aqua, Brassica napus Extract] marketed by {Science, TM} [INCI: Aqua, Glycerin, Malva sylvestris (Mallow) Extract, Mentha piperita Leaf Extract, Primula veris Extract, Alchemilla vulgaris Extract, Verónica officinalis Extract, Melissa officinalis Leaf Extract, Achillea millefolium Extract], Melawhite® [INCI: Leukocyte Extract , AHA] or Melfade®-J [INCI: Aqua, Arctostaphylos uva-ursi Leaf Extract, Glycerin, Magnesium Ascorbyl Phosphate] marketed by Pentapharm, Albatin® [INCI: Aminoethylphosphoric Acid, Butylene Glycol, Aqua] marketed by Exsymol, Tyrostat ^ TM} -11 [INCI: Aqua, Glycerin, Rumex occidentalis Extract] or Melanostatine®-5 [INCI: Dextran, Nonapeptide-1] marketed by Atrium Innovations, arbutin and its isomers, kojic acid and s us derivatives, vitamin C and its derivatives such as for example and without limitation the 6- O -palmitoilascorbic acid, dipalmitoilascorbic acid, the magnesium salt of ascorbic acid-2-phosphate (MAP), the sodium salt of ascorbic acid-2-phosphate (NAP), ascorbyl glucoside or ascorbyl tetraisopalmitate (VCIP) among others, retinol and its derivatives including tretinoin and isotretinoin, idebenone, hydroxybenzoic acid and its derivatives, flavonoids, soy extract, lemon extract, orange extract, ginkgo extract, cucumber extract, geranium extract, bearberry extract, carob extract, cinnamon extract, marjoram extract, rosemary extract, clove extract, soluble licorice extract, blackberry leaf extract, niacinamide, liquiritine, resorcinol and its derivatives, hydroquinone, α-tocopherol, γ-tocopherol, azelaic acid, azeloglycine, resveratrol, mercury salts, linoleic acid, α-lipoic acid, dihydrolipoic acid, alphahydro xyacids, betahydroxy acids, ellagic acid, ferulic acid, cinnamic acid, oleanolic acid, aloesin and its derivatives and / or inhibitors of serine proteases, such as, for example and without limiting sense, tryptase, trypsin or PAR-2 inhibitors, among others .
Las composiciones cosméticas o dermofarmacéuticas de la invención pueden incluir agentes que aumenten la absorción percutánea de las micelas mixtas, como por ejemplo y sin sentido limitativo dimetilsulfóxido, dimetilacetamida, dimetilformamida, tensioactivos, azona (1-dodecilazacicloheptan-2-ona), alcohol, urea, etodixidiglicol, acetona, propilenglicol o polietilenglicol entre otros. Asimismo, las composiciones cosméticas o dermofarmacéuticas objeto de la presente invención pueden aplicarse en las áreas locales a tratar mediante iontoforesis, sonoforesis, electroporación, parches microeléctricos, presión mecánica, gradiente de presión osmótica, cura oclusiva, microinyecciones o inyecciones sin agujas mediante presión, como por ejemplo inyecciones por presión de oxígeno, o cualquier combinación de ellas, con el fin de conseguir una mayor penetración de las micelas mixtas en el estrato córneo.Cosmetic compositions or Dermopharmaceuticals of the invention may include agents that increase percutaneous absorption of mixed micelles, as per example and without limitation dimethylsulfoxide, dimethylacetamide, dimethylformamide, surfactants, azone (1-dodecylazacycloheptan-2-one), alcohol, urea, ethoxydiglycol, acetone, propylene glycol or polyethylene glycol among others. Also, cosmetic compositions or dermopharmaceuticals object of the present invention can be applied in local areas to be treated by iontophoresis, sonophoresis, electroporation, microelectric patches, pressure mechanical, osmotic pressure gradient, occlusive cure, microinjections or injections without needles by pressure, as per example oxygen pressure injections, or any combination of them, in order to achieve greater penetration of mixed micelles in the stratum corneum.
Las composiciones de la invención también se pueden incorporar en sistemas de liberación sostenida cosméticos o dermofarmacéuticos.The compositions of the invention are also they can incorporate cosmetic sustained release systems or dermopharmaceuticals
El término "liberación sostenida" se utiliza en sentido convencional refiriéndose a un sistema de vehiculización de un compuesto o composición que proporciona la liberación gradual de dicho compuesto o composición durante un período de tiempo y preferiblemente, aunque no necesariamente, con niveles de liberación del compuesto o composición constantes a lo largo de un período de tiempo.The term "sustained release" is used conventionally referring to a system of vehiculization of a compound or composition that provides the gradual release of said compound or composition during a period of time and preferably, but not necessarily, with release levels of the compound or composition constant at over a period of time.
Ejemplos de sistemas de liberación sostenida son milipartículas, micropartículas, nanopartículas, nanopartículas sólidas lipídicas, esponjas, ciclodextrinas, vesículas, miliesferas, microesferas, nanoesferas, lipoesferas, milicápsulas, microcápsulas y nanocápsulas, los cuales se pueden añadir con el fin de conseguir una mayor penetración de la composición de micelas mixtas y/o mejorar las propiedades farmacocinéticas y farmacodinámicas de la misma.Examples of sustained release systems are miliparticles, microparticles, nanoparticles, nanoparticles lipid solids, sponges, cyclodextrins, vesicles, microspheres, microspheres, nanospheres, lipospheres, microcapsules, microcapsules and nanocapsules, which can be added in order to get greater penetration of the composition of mixed micelles and / or improve the pharmacokinetic and pharmacodynamic properties of the same.
Las formulaciones de liberación sostenida pueden prepararse mediante los métodos conocidos en el estado de la técnica. La cantidad de composición de micelas mixtas contenida en la formulación de liberación sostenida dependerá, por ejemplo, de la cinética y duración de la liberación de la composición de micelas mixtas de la invención.Sustained release formulations can be prepared by methods known in the state of the technique. The amount of mixed micelle composition contained in the sustained release formulation will depend, for example, on the Kinetics and duration of release of the micelle composition mixed of the invention.
Las composiciones cosméticas o dermofarmacéuticas de la presente invención pueden prepararse mediante los métodos convencionales conocidos por los expertos en la materia ("Harry's Cosmeticology", Eight edition 2000; "Remington: The Science and Practice of Pharmacy", Twentieth edition 2003). Las micelas mixtas de las composiciones de la presente invención pueden prepararse igualmente mediante los métodos conocidos por el experto en la materia.The cosmetic or dermopharmaceutical compositions of the present invention can be prepared by conventional methods known to those skilled in the art ("Harry's Cosmeticology ", Eight edition 2000; " Remington: The Science and Practice of Pharmacy ", Twentieth edition 2003). The mixed micelles of the compositions of the present invention can also be prepared by methods known to those skilled in the art.
Las formulaciones de aplicación tópica de la composición de la invención pueden presentarse en cualquier forma de administración sólida, líquida o semisólida, como por ejemplo y sin sentido limitativo, cremas, emulsiones múltiples tales como por ejemplo y sin sentido limitativo emulsiones de aceite y/o silicona en agua, emulsiones de agua en aceite y/o silicona, emulsiones del tipo agua/aceite/agua o agua/silicona/agua y emulsiones del tipo aceite/agua/aceite o silicona/agua/silicona, composiciones anhidras, dispersiones acuosas, aceites, leches, bálsamos, espumas, lociones, geles, soluciones hidroalcóholicas, soluciones hidroglicólicas, linimentos, sueros, jabones, champús, acondicionadores, serums, films de polisacáridos, ungüentos, mousses, pomadas, polvos, barras, lápices y vaporizadores o aerosoles (sprays), incluyendo las formulaciones de permanencia o (leave on) y las de enjuagado o (rinse-off). Estas formulaciones de aplicación tópica pueden ser incorporadas mediante las técnicas conocidas por los expertos en la materia a distintos tipos de accesorios sólidos tales como por ejemplo y sin sentido limitativo a distintos productos de línea de maquillaje tales como fondos de maquillaje, incluyendo fondos de maquillaje fluidos y fondos de maquillaje compactos, lociones desmaquillantes, leches desmaquillantes, correctores de ojeras, sombras de ojos, barras de labios, protectores labiales, brillos labiales y polvos entre otros. Las composiciones cosméticas o dermofarmacéuticas de la presente invención también pueden incorporarse a productos para el tratamiento y/o cuidado de las uñas y las cutículas tales como esmaltes, lociones quitaesmaltes y lociones quitacutículas entre otros.The topical application formulations of the Composition of the invention can be presented in any form of solid, liquid or semi-solid administration, for example and without limiting sense, creams, multiple emulsions such as by example and without limitation oil and / or silicone emulsions in water, water emulsions in oil and / or silicone, emulsions of the type water / oil / water or water / silicone / water and emulsions of the type oil / water / oil or silicone / water / silicone, anhydrous compositions, aqueous dispersions, oils, milks, balms, foams, lotions, gels, hydroalcoholic solutions, hydro-glycol solutions, liniments, serums, soaps, shampoos, conditioners, serums, films of polysaccharides, ointments, mousses, ointments, powders, bars, pencils and vaporizers or sprays, including permanence formulations or (leave on) and those for rinsing or (rinse-off). These application formulations Topical can be incorporated using techniques known to experts in the field to different types of solid accessories such as for example and without limiting sense to different makeup line products such as makeup backgrounds, including fluid makeup backgrounds and makeup backgrounds compact, cleansing lotions, cleansing milks, dark circles, eye shadows, lipsticks, lip protectors, lip gloss and powders among others. The cosmetic or dermopharmaceutical compositions of the present invention can also be incorporated into products for the treatment and / or care of nails and cuticles such as enamels, nail polish remover lotions and remover lotions between others.
La composición cosmética o dermofarmacéutica de la invención también puede adsorberse a polímeros orgánicos sólidos o soportes minerales sólidos como por ejemplo y sin sentido limitativo talco, bentonita, sílice, almidón o maltodextrina entre otros.The cosmetic or dermopharmaceutical composition of the invention can also be adsorbed to solid organic polymers or solid mineral supports such as for example and meaningless limiting talc, bentonite, silica, starch or maltodextrin between others.
La composición cosmética de la invención también puede incorporarse a tejidos, tejidos-no-tejidos (non-woven) y productos sanitarios que estén en contacto directo con la piel, pestañas, cabello y/o uñas del cuerpo, de modo que liberen las micelas mixtas de la composición de la invención bien por biodegradación del sistema de anclaje al tejido, tejido-no-tejido o producto sanitario o bien por la fricción de estos con el cuerpo, por la humedad corporal, por el pH de la piel o por la temperatura corporal. Asimismo, los tejidos y los tejidos-no-tejidos pueden emplearse para la confección de prendas que estén en contacto directo con la piel, cabello y/o uñas. De manera preferente, los tejidos, tejidos-no-tejidos y productos sanitarios que contienen la composición de la invención se emplean para tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías de la piel, pestañas, cabello y/o uñas asociadas a una excesiva pérdida de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas.The cosmetic composition of the invention also can be incorporated into tissues, non-woven fabrics (non-woven) and medical devices that are in direct contact with skin, eyelashes, hair and / or body nails, so that they release the mixed micelles of the composition of the invention either by biodegradation of the tissue anchoring system, non-woven fabric or product sanitary or by the friction of these with the body, by the body moisture, by skin pH or temperature bodily. Also, tissues and non-woven fabrics can be used for making garments that are in direct contact with the skin, hair and / or nails. Preferably, the tissues, non-woven fabrics and products sanitary fittings containing the composition of the invention are used for treatment and / or care of those conditions, disorders and / or pathologies of the skin, eyelashes, hair and / or nails associated with a excessive loss of water and / or altered barrier function of the skin, eyelashes, hair and / or nails.
Ejemplos de tejidos, tejidos-no-tejidos, prendas, productos sanitarios y medios de inmovilización de micelas pueden encontrarse descritos en la literatura y son conocidos en el estado de la técnica ("Impregnating Fabrics With Microcapsules", HAPPI May 1986; Int. J. Pharm. 2002, 242, 55-62; "Biofunctional Textiles and the Skin" Curr. Probl. Dermatol. 2006 v.3; J. Cont. Release 2004, 97, 313-320). Tejidos, tejidos-no-tejidos, prendas y productos sanitarios preferidos son vendas, gasas, camisetas, calcetines, medias, ropa interior, fajas, guantes, pañales, compresas, apositos, cubrecamas, toallitas, hidrogeles, parches adhesivos, parches no adhesivos, parches microeléctricos y/o mascarillas faciales.Examples of fabrics, non-woven fabrics, garments, sanitary products and means of immobilization of micelles can be described in the literature and are known in the state of the art (" Impregnating Fabrics With Microcapsules ", HAPPI May 1986; Int. J . Pharm . 2002, 242, 55-62; " Biofunctional Textiles and the Skin " Curr. Probl. Dermatol . 2006 v.3; J. Cont. Release 2004, 97, 313-320). Fabrics, non-woven fabrics, garments and sanitary products preferred are bandages, gauze, T-shirts, socks, socks, underwear, girdles, gloves, diapers, compresses, dressings, bedspreads, wipes, hydrogels, adhesive patches, non-adhesive patches, microelectric patches and / or facial masks.
Otro aspecto de la presente invención se refiere a una composición cosmética o dermofarmacéutica de micelas mixtas fosfolípido-tensioactivo, donde estas micelas mixtas se reconstituyen en liposomas en el estrato córneo de la piel encapsulando agua, para el tratamiento y/o cuidado de la piel, pestañas, cabello y/o uñas.Another aspect of the present invention relates to to a cosmetic or dermopharmaceutical composition of mixed micelles phospholipid-surfactant, where these mixed micelles they are reconstituted in liposomes in the stratum corneum of the skin encapsulating water, for the treatment and / or skin care, eyelashes, hair and / or nails.
En una realización particular, la presente invención se refiere a una composición cosmética o dermofarmacéutica de micelas mixtas fosfolípido-tensioactivo para el tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías asociadas a una excesiva pérdida de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas. De manera preferente, estas condiciones, desórdenes y/o patologías se seleccionan del grupo formado por envejecimiento de la piel (skin-aging), desórdenes de pigmentación de la piel y/o el pelo, sequedad de la piel, hiperseborrea, piel sensible, caspa, alopecia y pérdida del cabello, xeroderma, eczema, dermatitis, psoriasis, acné, rosácea, infecciones de las uñas, candidiasis y lupus eritematoso sistémico. Estas condiciones, desórdenes y/o patologías pueden tener origen en una pérdida excesiva de agua y/o alteración de la función barrera, o bien la condición, desorden y/o patología tiene una causa distinta a la pérdida excesiva de agua y/o alteración de la función barrera, pero provoca una excesiva pérdida de agua y/o una alteración de la función barrera.In a particular embodiment, the present invention refers to a cosmetic or dermopharmaceutical composition of mixed phospholipid-surfactant micelles for treatment and / or care of those conditions, disorders and / or pathologies associated with excessive water loss and / or the impaired barrier function of the skin, eyelashes, hair and / or nail. Preferably, these conditions, disorders and / or pathologies are selected from the group formed by aging of the skin (skin-aging), pigmentation disorders of the skin and / or hair, dry skin, hyperseborrhea, sensitive skin, Dandruff, alopecia and hair loss, xeroderma, eczema, dermatitis, psoriasis, acne, rosacea, nail infections, candidiasis and systemic lupus erythematosus. These conditions, disorders and / or pathologies may originate in a loss excessive water and / or alteration of the barrier function, or the condition, disorder and / or pathology has a cause other than excessive loss of water and / or impaired barrier function, but causes excessive water loss and / or an alteration of the barrier function
En el contexto de la presente invención, el
término "envejecimiento de la piel" se refiere a los cambios
que experimenta la piel con paso de la edad (cronoenvejecimiento) o
por exposición al sol (fotoenvejecimiento) o a agentes ambientales
como son el humo del tabaco, las condiciones climáticas extremas de
frío o viento, los contaminantes químicos o la polución, e incluye
todos los cambios externos visibles y así como perceptibles mediante
tacto, como por ejemplo y sin sentido limitativo, el desarrollo de
discontinuidades en la piel como arrugas, líneas finas, grietas,
irregularidades o asperezas, aumento del tamaño de los poros,
pérdida de la elasticidad, pérdida de la firmeza, pérdida de la
tersura, pérdida de la capacidad de recuperación de la deformación,
descolgamiento de la piel como el descolgamiento de las mejillas, la
aparición de bolsas bajo los ojos o la aparición de papada entre
otros, cambios en el color de la piel como manchas, rojeces, ojeras
o aparición de zonas hiperpigmentadas como manchas de la edad o
pecas entre otros, diferenciación anómala, hiperqueratinización,
elastosis, queratosis, aspecto de piel de naranja, pérdida de la
estructuración del colágeno y otros cambios histológicos del estrato
córneo, de la dermis, de la epidermis, del sistema vascular
(por ejemplo la aparición de venas de araña o telangiectasias) o de
aquellos tejidos próximos a la piel entre otros.In the context of the present invention, the term "skin aging" refers to changes that the skin undergoes with age (chrono-aging) or exposure to the sun (photo-aging) or to environmental agents such as tobacco smoke , extreme weather conditions of cold or wind, chemical pollutants or pollution, and includes all visible external changes and as well as perceptible by touch, such as without limitation, the development of discontinuities in the skin such as wrinkles, lines fine, cracks, irregularities or roughness, increased pore size, loss of elasticity, loss of firmness, loss of smoothness, loss of the ability to recover from deformation, sagging of the skin such as sagging of the cheeks , the appearance of bags under the eyes or the appearance of jowls among others, changes in skin color such as spots, redness, dark circles or appearance n of hyperpigmented areas such as age spots or freckles among others, abnormal differentiation, hyperkeratinization, elastosis, keratosis, orange peel appearance, loss of collagen structuring and other histological changes of the stratum corneum, dermis, epidermis , of the vascular system
(for example the appearance of spider veins or telangiectasias) or of those tissues close to the skin among others.
La composición cosmética o dermofarmacéutica de la presente invención puede ser una composición final, disponible para su aplicación sin que haya que realizar ningún procedimiento de concentración, disolución, dilución, dispersión, pulverización, esprayado o cualquier otro procedimiento similar conocido por el experto en la materia, o bien una composición intermedia a la que se realizarán uno o varios de los procedimientos anteriores o cualquier otro procedimiento conocido por el experto en la materia con el objeto de obtener una composición final.The cosmetic or dermopharmaceutical composition of the present invention may be a final composition, available for its application without having to perform any procedure of concentration, dissolution, dilution, dispersion, spraying, sprayed or any other similar procedure known to the expert in the field, or an intermediate composition to which perform one or more of the above procedures or any another procedure known to the person skilled in the art with the object of obtaining a final composition.
Otro aspecto de la presente invención se refiere al uso de una composición cosmética o dermofarmacéutica de micelas mixtas fosfolípido-tensioactivo, donde estas micelas mixtas se reconstituyen en liposomas en el estrato córneo de la piel encapsulando agua, en la preparación de una composición cosmética o dermofarmacéutica final para el tratamiento y/o cuidado de la piel, pestañas, cabello y/o uñas.Another aspect of the present invention relates to to the use of a cosmetic or dermopharmaceutical composition of micelles mixed phospholipid-surfactant, where these micelles mixed are reconstituted in liposomes in the stratum corneum of the skin encapsulating water, in the preparation of a cosmetic composition or final dermopharmaceutical for the treatment and / or skin care, eyelashes, hair and / or nails.
En una realización particular, la presente invención se refiere al uso de una composición cosmética o dermofarmacéutica de micelas mixtas fosfolípido-tensioactivo, donde estas micelas mixtas se reconstituyen en liposomas en el estrato córneo de la piel encapsulando agua, en la preparación de una composición cosmética o dermofarmacéutica final para el tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías asociadas a una excesiva pérdida de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas. De manera preferente, estas condiciones, desórdenes y/o patologías se seleccionan del grupo formado por envejecimiento de la piel (skin-aging), desórdenes de pigmentación de la piel y/o el pelo, sequedad de la piel, hiperseborrea, piel sensible, caspa, alopecia y pérdida del cabello, xeroderma, eczema, dermatitis, psoriasis, acné, rosácea, infecciones de las uñas, candidiasis y lupus eritematoso sistémico. Estas condiciones, desórdenes y/o patologías pueden tener origen en una pérdida excesiva de agua y/o alteración de la función barrera, o bien la condición, desorden y/o patología tiene una causa distinta a la pérdida excesiva de agua y/o alteración de la función barrera, pero provoca una excesiva pérdida de agua y/o una alteración de la función barrera.In a particular embodiment, the present invention refers to the use of a cosmetic composition or mixed micellar dermopharmaceutical phospholipid-surfactant, where these mixed micelles they are reconstituted in liposomes in the stratum corneum of the skin encapsulating water, in the preparation of a cosmetic composition or final dermopharmaceutical for the treatment and / or care of those conditions, disorders and / or pathologies associated with excessive loss of water and / or alteration of the barrier function of the skin, eyelashes, hair and / or nails. Preferably, you are conditions, disorders and / or pathologies are selected from the group formed by skin aging (skin-aging), skin and / or hair pigmentation disorders, dryness of the skin, hyperseborrhea, sensitive skin, dandruff, alopecia and loss of hair, xeroderma, eczema, dermatitis, psoriasis, acne, rosacea, nail infections, candidiasis and systemic lupus erythematosus. These conditions, disorders and / or pathologies may originate in excessive water loss and / or impaired barrier function, or either the condition, disorder and / or pathology has a cause other than excessive water loss and / or impaired barrier function, but causes excessive loss of water and / or an alteration of the barrier function
Otro aspecto de la presente invención se refiere a un método cosr?iético o dermofarmacéutico para el tratamiento y/o cuidada de la piel, pestañas, cabello y/o uñas, que comprende la aplicación de una composición cosmética o dermofarmacéutica de micelas mixtas fosfolípido-tensioactivo, donde estas micelas mixtas se reconstituyen en liposomas en el estrato córneo de la piel encapsulando agua.Another aspect of the present invention relates to to a cosmetic or dermopharmaceutical method for treatment and / or taken care of the skin, eyelashes, hair and / or nails, which includes the application of a cosmetic or dermopharmaceutical composition of mixed phospholipid surfactant micelles, where are you mixed micelles are reconstituted in liposomes in the stratum corneum of the skin encapsulating water.
En una realización particular, el método de tratamiento y/o cuidado de aquellas condiciones, desórdenes y/o patologías se encuentra asociado a una pérdida excesiva de agua y/o a la alteración de la función barrera de la piel, pestañas, cabello y/o uñas. De manera preferente, estas condiciones, desórdenes y/o patologías se seleccionan del grupo formado por envejecimiento de la piel (skin-aging), desórdenes de pigmentación de la piel y/o el pelo, sequedad de la piel, hiperseborrea, piel sensible, caspa, alopecia y pérdida del cabello, xeroderma, eczema, dermatitis, psoriasis, acné, rosácea, infecciones de las uñas, candidiasis y lupus eritematoso sistémico. Estas condiciones, desórdenes y/o patologías pueden tener origen en una pérdida excesiva de agua y/o alteración de la función barrera, o bien la condición, desorden y/o patología tiene una causa distinta a la pérdida excesiva de agua y/o alteración de la función barrera, pero provoca una excesiva pérdida de agua y/o una alteración de la función barrera.In a particular embodiment, the method of treatment and / or care of those conditions, disorders and / or pathologies is associated with excessive loss of water and / or to the alteration of the barrier function of the skin, eyelashes, hair and / or nails. Preferably, these conditions, disorders and / or pathologies are selected from the group formed by aging of the skin (skin-aging), pigmentation disorders of the skin and / or hair, dry skin, hyperseborrhea, sensitive skin, Dandruff, alopecia and hair loss, xeroderma, eczema, dermatitis, psoriasis, acne, rosacea, nail infections, candidiasis and systemic lupus erythematosus. These conditions, disorders and / or pathologies may originate in a loss excessive water and / or alteration of the barrier function, or the condition, disorder and / or pathology has a cause other than excessive loss of water and / or impaired barrier function, but causes excessive water loss and / or an alteration of the barrier function
La frecuencia de aplicación puede variar ampliamente dependiendo de las necesidades de cada sujeto, sugiriéndose un rango de aplicación desde una vez al mes hasta diez veces al día, preferentemente desde una vez a la semana hasta cuatro veces al día, más preferentemente desde tres veces por semana hasta tres veces al día, aún más preferentemente una o dos veces al día.The frequency of application may vary. widely depending on the needs of each subject, suggesting an application range from once a month to ten times a day, preferably from once a week to four times a day, more preferably from three times a week to three times a day, even more preferably once or twice a day.
Los siguientes ejemplos específicos que se proporcionan aquí sirven para ilustrar la naturaleza de la presente invención. Estos ejemplos se incluyen solamente con fines ilustrativos y no han de ser interpretados como limitaciones a la invención que aquí se reivindica.The following specific examples to be provided here serve to illustrate the nature of the present invention. These examples are included for purposes only. illustrative and should not be construed as limitations to the invention claimed here.
La figura 1 muestra una fotografía obtenida por microscopía de transmisión electrónica. Los números señalan 5 liposomas conteniendo fosfatidilcolina de tamaño 280 nm (1), 470 nm (2), 520 nm (3), (4) y 700 nm (5) reconstituidos en el estrato córneo a partir de la composición de micelas mixtas del ejemplo 1. El espacio interior de los liposomas está ocupado por agua del estrato córneo que queda encapsulada dentro de los liposomas reconstituidos.Figure 1 shows a photograph obtained by electron transmission microscopy. The numbers point 5 liposomes containing phosphatidylcholine size 280 nm (1), 470 nm (2), 520 nm (3), (4) and 700 nm (5) reconstituted in the stratum cornea from the mixed micelle composition of example 1. The interior space of the liposomes is occupied by water from the stratum corneum that is encapsulated within the liposomes reconstituted
La figura 2 muestra una fotografía obtenida por microscopía de transmisión electrónica. Los números señalan 5 liposomas conteniendo fosfatidilcolina de tamaño 320 nm (1), 190 nm (2), 160 nm (3), 270 nm (4) y 320 nm (5) reconstituidos en el estrato córneo a partir de la composición de micelas mixtas del ejemplo 2. El espacio interior de. los liposomas está ocupado por agua del estrato córneo que queda encapsulada dentro de los liposomas reconstituidos.Figure 2 shows a photograph obtained by electron transmission microscopy. The numbers point 5 liposomes containing phosphatidylcholine size 320 nm (1), 190 nm (2), 160 nm (3), 270 nm (4) and 320 nm (5) reconstituted in the stratum corneum from the composition of mixed micelles of the example 2. The interior space of. the liposomes is occupied by water of the stratum corneum that is encapsulated within the reconstituted liposomes.
La figura 3 muestra una fotografía obtenida por microscopía de transmisión electrónica. Los números señalan 2 liposomas conteniendo lecitina de tamaño 95 nm (1) y 180 nm (2) reconstituidos en el estrato córneo a partir de la composición de micelas mixtas del ejemplo 3. El espacio interior de los liposomas está ocupado por agua del estrato córneo que queda encapsulada dentro de los liposomas reconstituidos.Figure 3 shows a photograph obtained by electron transmission microscopy. The numbers point 2 liposomes containing 95 nm (1) and 180 nm (2) size lecithin reconstituted in the stratum corneum from the composition of mixed micelles from example 3. The inner space of the liposomes is occupied by water from the stratum corneum that is encapsulated within the reconstituted liposomes.
La figura 4 se obtuvo por microscopía de transmisión electrónica, muestra un liposoma que contienen fosfatidilserina, de tamaño 300 nm, reconstituido en el estrato córneo a partir de la composición de micelas mixtas del ejemplo 4. El espacio interior del liposoma está ocupado por agua del estrato córneo que queda encapsulada dentro del liposoma reconstituido.Figure 4 was obtained by microscopy of electronic transmission, shows a liposome containing phosphatidylserine, size 300 nm, reconstituted in the stratum cornea from the mixed micelle composition of example 4. The interior space of the liposome is occupied by stratum water cornea that is encapsulated within the reconstituted liposome.
\global\parskip0.950000\baselineskip\ global \ parskip0.950000 \ baselineskip
Todos los reactivos y disolventes son de calidad para síntesis y se usan sin ningún tratamiento adicional.All reagents and solvents are of quality for synthesis and are used without any additional treatment.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron 20,4 g del tensioactivo no iónico n-octil \beta-D-glucósido en 50 ml de agua. Una vez hecha la disolución, se añadieron 7,8 g del lípido LIPOID® S 100 (ésteres de ácidos grasos de fosfatidilcolina) [INCI: Phosphatidylcholine], se mezcló bien y enrasó con agua hasta 100 ml. Se volvió a mezclar calentando la dispersión hasta 40ºC y se utilizó un baño de ultrasonidos para facilitar la homogeneización de la solución. Las micelas mixtas se formaron cuando todo el lípido estuvo solubilizado y se obtuvo una dispersión transparente.20.4 g of the non-ionic surfactant was dissolved n-octyl β-D-glycoside in 50 ml of Water. Once the solution was made, 7.8 g of the lipid was added LIPOID® S 100 (phosphatidylcholine fatty acid esters) [INCI: Phosphatidylcholine], mixed well and made up to 100 ml with water. It was mixed again by heating the dispersion to 40 ° C and used an ultrasonic bath to facilitate homogenization of the solution. Mixed micelles formed when all lipid It was solubilized and a clear dispersion was obtained.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1, pero se sustituyó n-octil \beta-D-glucósido por una mezcla de tensioactivos de octilglucósido y decilglucósido, ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside].Mixed micelles were prepared in the manner described in example 1, but n-octyl was substituted β-D-glycoside by a mixture of octylglucoside and decylglucoside surfactants, ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside].
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 2, pero se sustituyó el fosfolípido LIPOID® S 100 [INCI: Phosphatidylcholine] por lecitina LIPOID® P 20 [INCI: Lecithin], La cantidad de tensioactivos fue de 32 g y la cantidad de fosfolípidos de 3 g.Mixed micelles were prepared in the manner described in example 2, but the phospholipid LIPOID® S was replaced 100 [INCI: Phosphatidylcholine] per LIPOID® P 20 lecithin [INCI: Lecithin], The amount of surfactants was 32 g and the amount of 3 g phospholipids.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1, pero se sustituyó n-octil \beta-D-glucósido por dodecilmaltósido y el fosfolípido LIPOID® S 100 [INCI: Phosphatidylcholine] se sustituyó por fosfatidilserina. La cantidad de dodecilmaltósido fue de 16 g y la cantidad de fosfatidilserina de 6,8 g.Mixed micelles were prepared in the manner described in example 1, but n-octyl was substituted β-D-glycoside by dodecilmaltósido and the phospholipid LIPOID® S 100 [INCI: Phosphatidylcholine] was replaced by phosphatidylserine. The amount of dodecylmaltoside was 16 g and the amount of phosphatidylserine of 6.8 g
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1. La cantidad de tensioactivo fue de 23 g, la de fosfolípido 6 g y se añadió 1 g del lípido CERAMIDE III (N-estearoilfitoesfingosina) a la vez que el fosfolípido.The mixed micelles were prepared in the manner described in Example 1. The amount of surfactant was 23 g, that of phospholipid 6 g and 1 g of the CERAMIDE III lipid ( N- stearoylphosphingosine) was added together with the phospholipid.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1. La cantidad de tensioactivo TWEEN® 80 [INCI: Polysorbate 80] fue de 8 g, la de fosfolípido fosfatidilinositol 5 g y se añadió 1 g de colesterol a la vez que el fosfolípido. El disolvente fue etanol.Mixed micelles were prepared in the manner described in example 1. The amount of TWEEN® 80 surfactant [INCI: Polysorbate 80] was 8 g, that of phospholipid 5 g phosphatidylinositol and 1 g of cholesterol was added at the same time as the phospholipid The solvent was ethanol.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1. La cantidad de tensioactivo nonoxinol-9 fue de 78 g, la de fosfolípido fosfatidildiglicerol 1,4 g y se añadieron 0,4 g de MYRITOL® 318 [INCI: Caprylic/Capric Triglyceride] a la vez que el fosfolípido. El disolvente fue glicerina.Mixed micelles were prepared in the manner described in example 1. The amount of surfactant Nonoxynol-9 was 78 g, that of phospholipid phosphatidyldiglycerol 1.4 g and 0.4 g of MYRITOL® 318 was added [INCI: Caprylic / Capric Triglyceride] at the same time as the phospholipid. He Solvent was glycerin.
\global\parskip1.000000\baselineskip\ global \ parskip1.000000 \ baselineskip
Las micelas mixtas se prepararon de la manera descrita en el ejemplo 1. La cantidad de tensioactivo dodecilbetaína fue de 8 g, la de fosfolípido fosfatidiletanolamina 8 g. El disolvente fue propilenglicol.Mixed micelles were prepared in the manner described in example 1. The amount of dodecyl betaine surfactant it was 8 g, that of phospholipid phosphatidylethanolamine 8 g. He solvent was propylene glycol.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron bajo agitación en 50 ml de agua 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,1 g de imidazolidinil urea, 2 g de cafeína y 1 g de carnitina. Una vez disueltos se añadieron bajo agitación 3 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] y a continuación 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó con agua hasta 100 ml.They were dissolved under stirring in 50 ml of water 0.5 g of PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.1 g of imidazolidinyl urea, 2 g of caffeine and 1 g of carnitine. One time dissolved 3 g of phosphatidylcholine was added under stirring LIPOID® S 100 [INCI: Phosphatidylcholine] and then 0.4 g of xanthan gum Finally, 30 g of ORAMIX CG110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] 60% slowly and with stirring to not foam and flush with water up to 100 ml.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron bajo agitación en 50 ml de agua 30 g de ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside], y a continuación 0,2 g de diclofenaco sódico. Una vez disueltos se añadieron bajo agitación 7 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] lentamente para no formar espuma y se enrasó con agua hasta 100 ml.They were dissolved under stirring in 50 ml of water 30 g of ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside], and then 0.2 g of diclofenac sodium. One time dissolved 7 g of phosphatidylcholine was added under stirring LIPOID® S 100 [INCI: Phosphatidylcholine] slowly to not form foam and flush with water up to 100 ml.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron bajo agitación en 50 ml de agua 30 g de ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside], y a continuación 0,2 g de diclofenaco sódico. Una vez disueltos se añadieron bajo agitación 3g de LIPOID® P20 [INCI: Lecithin] lentamente para no formar espuma y se enrasó con agua hasta 100 ml.They were dissolved under stirring in 50 ml of water 30 g of ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside], and then 0.2 g of diclofenac sodium. One time dissolved were added under stirring 3g of LIPOID® P20 [INCI: Lecithin] slowly to not foam and flush with water up to 100 ml
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La composición se preparó de la manera descrita en el ejemplo 9. Inicialmente se disolvieron 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,1 g de imidazolidinil urea, 2 g de lisina y 10 g de solución acuosa de SERILESINE® [INCI: Hexapeptide-10] al 0,05%. A continuación se añadieron 4 g de lecitina LIPOID® P20 [INCI: Lecithin] y 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó hasta 100 ml de agua.The composition was prepared in the manner described in Example 9. Initially 0.5 g of PHENONIP® was dissolved [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.1 g of imidazolidinyl urea, 2 g of lysine and 10 g of aqueous solution of SERILESINE® [INCI: Hexapeptide-10] at 0.05%. Then you added 4 g of LIPOID® P20 lecithin [INCI: Lecithin] and 0.4 g of xanthan gum Finally, 30 g of ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] 60% slowly and with stirring to not foam and make up to 100 ml of Water.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La composición se preparó de la manera descrita en el ejemplo 9. Inicialmente se disolvieron 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,1 g de imidazolidinil urea, 0,1 g de ácido hialurónico y 5 g de glicerina. A continuación se añadieron 3 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] y 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó hasta 100 ml de agua.The composition was prepared in the manner described in Example 9. Initially 0.5 g of PHENONIP® was dissolved [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.1 g of imidazolidinyl urea, 0.1 g of hyaluronic acid and 5 g of glycerin. Then they were added 3 g of phosphatidylcholine LIPOID® S 100 [INCI: Phosphatidylcholine] and 0.4 g of xanthan gum. Finally, 30 g of ORAMIX CG110 was added [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] 60% slowly and with stirring so as not to foam and flush up to 100 ml of Water.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La composición se preparó de la manera descrita en el ejemplo 9. Inicialmente se disolvieron 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,1 g de imidazolidinil urea, 2 g de glucósido de ascorbilo y 5 g de arbutina. A continuación se añadieron 3 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] y 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó hasta 100 ml de agua.The composition was prepared in the manner described in Example 9. Initially 0.5 g of PHENONIP® was dissolved [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.1 g of imidazolidinyl urea, 2 g of ascorbyl glycoside and 5 g of arbutin. Then you added 3 g of phosphatidylcholine LIPOID® S 100 [INCI: Phosphatidylcholine] and 0.4 g of xanthan gum. Finally added 30 g of ORAMIX CG110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] 60% slowly and with agitation to not foam and it was made up to 100 ml of water.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron bajo agitación en 50 ml de agua 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,1 g de imidazolidinil urea y 5 g de una disolución acuosa de ALDENINE® [INCI: Hydrolized Wheat Protein, Hydrolized Soy Protein, Tripeptide-1]. Una vez disueltos, se añadieron bajo agitación 3 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] seguidos de 0,5 g de acetato de tocoferol, y a continuación 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó con agua hasta 100 ml.They were dissolved under stirring in 50 ml of water 0.5 g of PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.1 g of imidazolidinyl urea and 5 g of an aqueous solution of ALDENINE® [INCI: Hydrolized Wheat Protein, Hydrolized Soy Protein, Tripeptide-1]. Once dissolved, they were added under Stirring 3 g of phosphatidylcholine LIPOID® S 100 [INCI: Phosphatidylcholine] followed by 0.5 g of tocopherol acetate, and a then 0.4 g of xanthan gum. Finally, 30 g of ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] at 60% slowly and with agitation to not foam and flush with water up to 100 ml.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Se disolvieron bajo agitación en 50 ml de agua 0,5 g de PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0,3 g de sorbato de potasio y 0,5 g de caprililglicol y se calentó a 30ºC. Una vez disueltos, se añadieron bajo agitación 4 g de fosfatidilcolina LIPOID® S 100 [INCI: Phosphatidylcholine] seguidos de 7,5 g de ANTARCTICINE® [INCI: Pseudoalteromonas Ferment Extract], 20 g de una disolución acuosa de LEUPHASYL® [INCI: Pentapeptide-18] al 0,05%, y 0,025 g del péptido inhibidor de metaloproteasas Ac-L-Arg-L-His-L-His-L-Cit-OH, y a continuación 0,4 g de goma xantana. Por último, se añadieron 30 g de ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl/Capryl Glucoside] al 60% lentamente y con agitación para no formar espuma y se enrasó con agua hasta 100 ml.They were dissolved under stirring in 50 ml of water 0.5 g of PHENONIP® [INCI: Phenoxyethanol, Methylparaben, Ethylparaben, Butylparaben, Propylparaben, Isobutylparaben], 0.3 g of potassium sorbate and 0.5 g of caprililglicol and heated to 30 ° C. Once dissolved, 4 g of phosphatidylcholine LIPOID® S 100 [INCI: Phosphatidylcholine] followed 7.5 g of ANTARCTICINE® [INCI: Pseudoalteromonas Ferment Extract], 20 g of an aqueous solution of LEUPHASYL® [INCI: 0.05% Pentapeptide-18], and 0.025 g of the peptide metalloprotease inhibitor Ac-L-Arg-L-His-L-His-L-Cit-OH, and then 0.4 g of xanthan gum. Finally, 30 were added g of ORAMIX CG 110 [INCI: Water (Aqua), Caprylyl / Capryl Glucoside] 60% slowly and with stirring to not foam and flush with water up to 100 ml.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
Después de 18 horas tras la aplicación de las composiciones de los ejemplos 1 a 4 en estrato córneo de cerdo se separó la epidermis de cerdo sin pelo y se aislaron las láminas de estrato córneo. A continuación se cortó el estrato córneo en finas láminas de 2x1 mm aproximadamente. Las láminas se fijaron con glutaraldehído 5% en tampón de cacodilato sódico 0,1 M a pH=7,2 y se postfijaron en RuO_{4} 0,2% en tampón de cacodilato sódico 0,1M a pH=6,8 con ferrocianuro sódico 0,25% (w/v). Tras una hora, la solución de RuO_{4} se cambió por RuO_{4} fresco para obtener una fijación óptima. Tras un lavado con tampón, las muestras de tejido fueron criofijadas mediante rápida congelación con nitrógeno líquido a -196ºC.After 18 hours after the application of the compositions of examples 1 to 4 in pig stratum stratum are separated the hairless pig epidermis and the slices were isolated stratum corneum Then the stratum corneum was cut into thin 2x1 mm sheets approximately. The sheets were fixed with 5% glutaraldehyde in 0.1 M sodium cacodylate buffer at pH = 7.2 and postfixed in RuO 4 0.2% in 0.1M sodium cacodylate buffer at pH = 6.8 with 0.25% sodium ferrocyanide (w / v). After an hour, the RuO_ {4} solution was changed to fresh RuO_ {4} to get an optimal fixation. After washing with buffer, the samples of tissue were cryofixed by rapid freezing with nitrogen liquid at -196 ° C.
Las muestras criofijadas fueron analizadas en un AFS (Automatic Freeze Substitution) system (Leica). El tejido se criosubstituyó a -90ºC durante 48 h usando metanol conteniendo un 1% de OsO_{4}, 9.5% acetato de uranilo y 3% de glutaraldehído. Pasadas las 48 horas, la temperatura se aumentó a -50ºC tras lo que las muestras se lavaron tres veces con metanol y secuencialmente se fue sustituyendo la solución de metanol por el medio Lowicryl HM20 (100%). Esta resina se reemplazó tras 24 y 48 horas por nuevo medio. Finalmente, las muestras se sometieron a radiación UVA para permitir la polimerización y se hicieron cortes ultrafinos (Ultracut UCT, Leica) que se transfirieron a una placa Formvar y se examinaron en un microscopio de transmisión electrónica Hitachi 600.Cryofixed samples were analyzed in a AFS (Automatic Freeze Substitution) system (Leica). The tissue is cryosubstituted at -90 ° C for 48 h using 1% methanol of OsO4, 9.5% uranyl acetate and 3% glutaraldehyde. After 48 hours, the temperature was increased to -50 ° C after what the samples were washed three times with methanol and sequentially was replacing the methanol solution with the Lowicryl HM20 medium (100%) This resin was replaced after 24 and 48 hours by new medium. Finally, the samples were subjected to UVA radiation to allow the polymerization and ultrafine cuts were made (Ultracut UCT, Leica) that were transferred to a Formvar plate and examined in a Hitachi 600 electronic transmission microscope.
Las figuras 1 a 4 muestran liposomas conteniendo agua reconstituidos en el estrato corneo de piel de cerdo para las composiciones de los ejemplos 1 a 4 respectivamente.Figures 1 to 4 show liposomes containing reconstituted water in the pig skin stratum corneum for compositions of examples 1 to 4 respectively.
Claims (26)
\global\parskip0.930000\baselineskip\ global \ parskip0.930000 \ baselineskip
\global\parskip0.900000\baselineskip\ global \ parskip0.900000 \ baselineskip
\global\parskip1.000000\baselineskip\ global \ parskip1.000000 \ baselineskip
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800596A ES2335636B1 (en) | 2008-02-29 | 2008-02-29 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. |
PCT/EP2009/001405 WO2009106338A2 (en) | 2008-02-29 | 2009-02-27 | Cosmetic of dermopharmaceutical composition of mixed micelles |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200800596A ES2335636B1 (en) | 2008-02-29 | 2008-02-29 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2335636A1 ES2335636A1 (en) | 2010-03-30 |
ES2335636B1 true ES2335636B1 (en) | 2011-05-11 |
Family
ID=41016508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES200800596A Expired - Fee Related ES2335636B1 (en) | 2008-02-29 | 2008-02-29 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2335636B1 (en) |
WO (1) | WO2009106338A2 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013502436A (en) | 2009-08-21 | 2013-01-24 | ターゲッティド デリバリー テクノロジーズ リミテッド | Vesicular preparation |
KR101684909B1 (en) * | 2010-11-26 | 2016-12-09 | (주)아모레퍼시픽 | Spray type aerosol cosmetic composition |
US9248089B2 (en) | 2011-11-07 | 2016-02-02 | Grf (Wuhan) Biotechnology Inc. | Peptide-based compounds as inhibitors of neurotransmitter secretion |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
GB201208384D0 (en) * | 2012-05-14 | 2012-06-27 | Sequessome Technology Holdings Ltd | Vesicular formulations, uses and methods |
ITRM20120267A1 (en) * | 2012-06-08 | 2013-12-09 | Antonio Chiarella | MICRONIZABLE LIQUID FORMULATION FOR THERAPEUTIC TREATMENT OF ACNE AND OTHER RELATED SKIN PATHOLOGIES |
CN102961779B (en) * | 2012-12-04 | 2014-10-22 | 深圳市宜丽环保科技有限公司 | Sanitary towel core plate with plant bacteriostatic and odor removing functions |
CN103212109A (en) * | 2013-04-17 | 2013-07-24 | 王伟 | Core sheet for physio-therapeutic towel |
GB201313735D0 (en) * | 2013-07-31 | 2013-09-11 | Pro Bono Internat Trading Ltd | Vesicles |
SG11201600424VA (en) * | 2013-07-31 | 2016-02-26 | Sequessome Technology Holdings Ltd | Vesicles |
WO2017001625A1 (en) | 2015-06-30 | 2017-01-05 | Sequessome Technology Holdings Limited | Multiphasic compositions |
US10966914B2 (en) | 2017-06-14 | 2021-04-06 | Counter Brands, Llc | Skin mimicking emulsion |
CN109330994A (en) * | 2018-11-28 | 2019-02-15 | 杭州普施康生物科技有限公司 | A kind of elemene solid lipid nano granule and preparation method thereof |
KR20210107772A (en) * | 2018-12-26 | 2021-09-01 | 니폰 세이카 가부시키가이샤 | Whitening agent, hyaluronic acid production promoter, collagen production promoter, intracellular active oxygen scavenger, irritation emollient, wrinkle improvement agent, complex, cosmetic and external skin agent |
US11369552B1 (en) | 2020-09-11 | 2022-06-28 | Elena Yurievna Komarova | Aqueous nail polish remover |
IT202200002549A1 (en) * | 2022-02-11 | 2023-08-11 | Sferalp Sa | Method for the preparation of an oil formulated for the formation of a micellar dispersion in water and oil composition made with the said method |
CN115282081B (en) * | 2022-07-05 | 2024-07-09 | 浙江东印化妆品有限公司 | Efficient whitening and freckle-fading and seal-repairing efficacy composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2740153B2 (en) * | 1995-03-07 | 1998-04-15 | エフ・ホフマン−ラ ロシユ アーゲー | Mixed micelle |
DE19710149A1 (en) * | 1997-03-12 | 1998-09-17 | Henkel Kgaa | Body cleanser |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
BRPI0614136A2 (en) * | 2005-08-05 | 2018-09-04 | Basf Catalysts Llc | exhaust article and method of treating exhaust current from a diesel engine |
-
2008
- 2008-02-29 ES ES200800596A patent/ES2335636B1/en not_active Expired - Fee Related
-
2009
- 2009-02-27 WO PCT/EP2009/001405 patent/WO2009106338A2/en active Application Filing
Non-Patent Citations (1)
Title |
---|
A. M. FADDA ET AL. "{}Phospholipid-detergent systems: effects of polysorbates on the release of liposomal caffeine"{} IL FARMACO, 1998, Vol 53, páginas 650-654. Página 651, columna derecha, párrafo 2; página 652, columna izquierda, párrafo 3; página 653, columna izquierda. * |
Also Published As
Publication number | Publication date |
---|---|
WO2009106338A2 (en) | 2009-09-03 |
WO2009106338A3 (en) | 2010-02-25 |
ES2335636A1 (en) | 2010-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2335636B1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION OF MIXED MICELAS. | |
ES2336995B1 (en) | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION FOR SKIN CARE, HAIR LEATHER AND NAILS. | |
ES2384060B1 (en) | LIPID NANOPARTICLES CAPSULES. | |
ES2390033B1 (en) | EXOPOLISACÁRIDO FOR THE TREATMENT AND / OR CARE OF SKIN, MUCOSAS, HAIR AND / OR NAILS. | |
KR102217951B1 (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails | |
KR102448943B1 (en) | Cosmetic and/or pharmaceutical composition containing a bacterial extracellular product from pseudoalteromonas antarctica, and use thereof | |
ES2732908T3 (en) | Nanocapsules containing microemulsions | |
CN102596164B (en) | Cosmetic preparation, skin preparations for extenal use and medical instrument | |
KR20150135425A (en) | Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails | |
ES2654345T3 (en) | Exopolysaccharide for the treatment and / or care of skin, mucous membranes, hair and / or nails |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20100330 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2335636 Country of ref document: ES Kind code of ref document: B1 Effective date: 20110428 |
|
FD2A | Announcement of lapse in spain |
Effective date: 20180924 |